Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
June 01 2016 - 4:48PM
Edgar (US Regulatory)
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-206710
PROSPECTUS SUPPLEMENT
(To Prospectus dated September 10, 2015)
Up to $35,000,000
Common Shares
_______________
We have entered into a Controlled Equity
Offering
SM
sales agreement with Cantor Fitzgerald & Co. relating to our common shares offered by this prospectus
supplement. In accordance with the terms of the sales agreement, we may offer and sell through this prospectus supplement common
shares having an aggregate offering price of up to $35,000,000 from time to time through Cantor Fitzgerald & Co., acting as
our sales agent.
Sales of our common shares, if
any, under this prospectus supplement may be made in sales deemed to be “at the market offerings” as
defined in Rule 415 promulgated under the Securities Act of 1933, as amended, or the Securities Act, including sales made
directly on or through the NASDAQ Global Market, the existing trading market for our common shares, sales made to or through
a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of
sale or at prices related to such prevailing market prices, and/or any other method permitted by law, including in
negotiated transactions with our prior written consent.
We will pay Cantor Fitzgerald & Co.
a fixed commission rate equal to 3.25% of the gross sales price per common share sold. In connection with the sale of our common
shares on our behalf, Cantor Fitzgerald & Co. will be deemed to be an “underwriter” within the meaning of the Securities
Act and the compensation of Cantor Fitzgerald & Co. will be deemed to be underwriting commissions or discounts. Subject to
the terms of the sales agreement, Cantor Fitzgerald & Co. will use its commercially reasonable efforts to sell on our behalf
any shares to be offered under the sales agreement, consistent with its normal trading and sales practices, on mutually agreed
terms between Cantor Fitzgerald & Co. and us.
Our common shares are listed on the NASDAQ
Global Market under the symbol “EARS.” The last recorded sale price of our common shares on the NASDAQ Global Market
on May 26, 2016 was $3.37 per share.
Thomas Meyer, our Chief Executive Officer,
or the Share Lender, has entered into a share lending agreement with Cantor Fitzgerald & Co., or the Share Borrower, to facilitate
the timely settlement of common shares sold under this prospectus supplement due to certain Swiss legal requirements with respect
to the issuance of common shares that could otherwise delay settlement. See “Related Party Transactions.”
Investing in our common shares involves
a high degree of risk. You should carefully consider all of the information set forth in this prospectus supplement, the accompanying
base prospectus and the documents incorporated by reference in this prospectus supplement before deciding to invest in our common
shares. See “
Risk Factors
” beginning on page S-6 of this prospectus supplement and in the documents incorporated
by reference in the accompanying prospectus.
Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of our common shares, or determined if this prospectus
supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
_______________
The date of this prospectus
supplement is June 1, 2016
table
of contents
_______________
Prospectus
Supplement
Page
Prospectus
Page
i
About This
Prospectus Supplement
This document consists of two parts. The
first part is the prospectus supplement, which describes the specific terms of this offering. The second part is the prospectus,
which describes more general information, some of which may not apply to this offering. You should read both this prospectus supplement
and the accompanying prospectus, together with the additional information described under the heading “Where You Can Find
More Information and Incorporation by Reference.”
Unless expressly stated or the context
otherwise requires, all references in this prospectus supplement to “Auris Medical,” or the “Company,”
“we,” “our,” “ours,” “us” or similar terms refer to Auris Medical Holding AG, a
Swiss corporation, together with its subsidiaries.
The terms “dollar,” “USD”
or “$” refer to U.S. dollars and the terms “Swiss Franc” and “CHF” refer to the legal currency
of Switzerland.
This prospectus supplement, the accompanying
prospectus and any issuer free writing prospectus may be used only for the purpose for which they have been prepared. No one is
authorized to give information other than that contained in or incorporated by reference into this prospectus supplement and the
accompanying prospectus and any issuer free writing prospectus. We have not, and the underwriter has not, authorized any other
person to provide you with different information. We and the underwriter take no responsibility for, and can provide no assurance
as to the reliability of, any other information that others may give you.
We are not, and the underwriter is not,
making an offer to sell the common shares in any jurisdiction where the offer or sale is not permitted. You should assume that
the information appearing in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference
is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have
changed since such dates. Neither this prospectus supplement nor the accompanying prospectus or any issuer free writing prospectus
constitutes an offer, or a solicitation on our behalf or on behalf of the underwriter, to subscribe for and purchase any of the
common shares and may not be used for or in connection with an offer or solicitation by anyone in any jurisdiction in which such
an offer or solicitation is not authorized or to any person to whom it is unlawful to make such an offer or solicitation.
Forward-Looking
Statements
This prospectus supplement, the accompanying
prospectus and documents incorporated by reference herein and therein contain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of
1934, as amended, or the Exchange Act. Many of the forward-looking statements contained in this prospectus supplement can be identified
by the use of words such as “anticipate,” “believe,” “could,” “expect,” “should,”
“plan,” “intend,” “will,” “estimate” and “potential,” among others,
or the negatives thereof.
Such forward-looking statements include,
but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on
our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements
due to various factors, including, but not limited to those identified under the section “Item 3. Key Information—D.
Risk factors” in our Annual Report on Form 20-F for the year ended December 31, 2015, incorporated by reference herein. These
risks and uncertainties include factors relating to:
|
·
|
our operation as a development stage company with limited operating history and a history of operating losses;
|
S-i
|
·
|
our need for substantial additional funding before we can expect to become profitable from sales of our products;
|
|
·
|
our dependence on the success of AM-101 and AM-111, which are still in clinical development and may eventually prove to be
unsuccessful;
|
|
·
|
the chance that we may become exposed to costly and damaging liability claims resulting from the testing of our product candidates
in the clinic or in the commercial stage;
|
|
·
|
the chance our clinical trials may not be completed on schedule, or at all, as a result of factors such as delayed enrollment
or the identification of adverse effects;
|
|
·
|
uncertainty surrounding whether any of our product candidates will receive regulatory approval, which is necessary before they
can be commercialized;
|
|
·
|
if our product candidates obtain regulatory approval, our being subject to expensive ongoing obligations and continued regulatory
overview;
|
|
·
|
enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval and commercialization;
|
|
·
|
the chance that we do not obtain orphan drug exclusivity for AM-111, which would allow our competitors to sell products that
treat the same conditions;
|
|
·
|
dependence on governmental authorities and health insurers establishing adequate reimbursement levels and pricing policies;
|
|
·
|
our products may not gain market acceptance, in which case we may not be able to generate product revenues;
|
|
·
|
our reliance on our current strategic relationships with INSERM or Xigen and the potential failure to enter into new strategic
relationships;
|
|
·
|
our reliance on third parties to conduct our nonclinical and clinical trials and on third-party single-source suppliers to
supply or produce our product candidates; and
|
|
·
|
other risk factors discussed under “Risk Factors.”
|
Although we believe that the expectations
reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
Forward-looking statements speak only as of the date they are made, and we do not undertake any obligation to update them in light
of new information or future developments or to release publicly any revisions to these statements in order to reflect later events
or circumstances or to reflect the occurrence of unanticipated events.
S-ii
Summary
The following summary highlights certain
information contained elsewhere in this prospectus supplement and the accompanying prospectus or in the documents incorporated
by reference herein. It may not contain all of the information that you should consider before investing in the common shares.
For a more complete discussion of the information you should consider before investing in the common shares, you should carefully
read this entire prospectus supplement, the accompanying prospectus and the incorporated documents.
Our Business
We are a clinical-stage biopharmaceutical
company focused on the development of novel products for the treatment of inner ear disorders. Our most advanced product candidate,
AM-101, is in Phase 3 clinical development for acute inner ear tinnitus under a special protocol assessment, or SPA, from the U.S.
Food and Drug Administration, or FDA. We are also developing AM-111 for acute inner ear hearing loss, or ASNHL. Both acute inner
ear tinnitus and hearing loss are conditions for which there is high unmet medical need, and we believe that we have the potential
to be the first to market in these indications.
We believe we are currently the clinically
most advanced company working on inner ear therapeutics. We believe that AM-101 and AM-111 are the only drug candidates that have
demonstrated positive efficacy in randomized placebo-controlled clinical trials in acute inner ear tinnitus and acute inner ear
hearing loss. Our products are protected through intellectual property rights and, in addition, orphan drug status has been granted
to AM-111.
Our product candidates are injected under
local anesthesia into the middle ear by a technique called intratympanic injection. Once injected into the middle ear, the active
substance, which is formulated in a biocompatible gel, diffuses into the inner ear. The procedure is short, safe, has a long history
of use and allows for highly targeted drug delivery with minimal systemic exposure. It is performed by an ear, nose and throat,
or ENT, specialist on an outpatient basis over one or more visits.
Our Product Candidates
Our lead product candidate, AM-101, is
targeting acute inner ear tinnitus. Tinnitus, frequently perceived as a ringing in the ears, is the perception of sound when no
external sound is present. Similar to pain, it is an unwanted, unpleasant and thus distressing sensation. Tinnitus may result in
further symptoms such as inability to concentrate, irritability, anxiety, insomnia, and clinical depression. In many cases, tinnitus
significantly impairs quality of life and affects normal day-to-day activities.
Tinnitus is categorized as acute during
the three months after onset and chronic when it persists for more than three months. Approximately 25% of American adults (50
million people) have experienced tinnitus with nearly 8% of American adults (16 million people) having frequent occurrences. Epidemiological
studies reveal comparable prevalence rates for Europe. Among the tinnitus patients seen by general practitioners and ENT specialists
in the United States and the top five European markets who reported seeing at least one tinnitus patient in the previous three
months, approximately 36% of patients sought medical treatment during the first three months following tinnitus onset.
Possible causes of acute inner ear tinnitus include traumatic insult such as exposure to excessive noise,
or middle ear infection (otitis media, or OM). We have conducted Phase 2 trials in this specific tinnitus population with AM-101,
which demonstrated a favorable safety profile. Furthermore, in our Phase 2 clinical trials, AM-101 showed a dose dependent, persistent
and clinically relevant improvement, as compared to the placebo, in subjective tinnitus loudness as well as other patient reported
outcomes, such as tinnitus annoyance, tinnitus severity, sleep difficulties and general tinnitus impact. Our Phase 3 clinical program,
which is similar in design to our Phase 2 trial design, is being conducted under an SPA from the FDA and also incorporates guidance
from the European Medicines Agency, or EMA. The Phase 3 clinical program is comprised of two Phase 3 studies, one in North America
(Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 2, or TACTT2) and one in Europe (Efficacy and Safety
of AM-101 in the Treatment of Acute Peripheral Tinnitus 3, or TACTT3), and two open label follow-on
|
studies, AM-101 in the Post-Acute
Treatment of Peripheral Tinnitus 1 and 2, or AMPACT1 and AMPACT2. Enrollment of patients in TACTT2 was completed in the first
quarter of 2016 and is expected to be completed in TACTT3 a few months later. We expect to have top-line results from the
first Phase 3 trial for AM-101 in the third quarter of 2016, with results for the second trial following a few months later.
We believe that AM-101 has the potential to become the first product approved for the treatment of acute inner ear
tinnitus.
Our second product candidate, AM-111, is
being developed for the treatment of ASNHL. In sensorineural hearing loss, which is also referred to as inner ear hearing loss,
there is damage to the sensory cells of the inner ear or the auditory nerve. Hearing loss is a heterogeneous disorder of many forms
with a variety of causes. ASNHL may be triggered by a variety of insults, such as exposure to excessively loud sound, infection,
inflammation or certain ototoxic drugs. These insults may also result in tinnitus. In the United States, more than 66,000 patients
covered by health insurance are treated for sudden deafness annually. There are no currently approved pharmaceutical treatments
for this patient population in the United States.
In our Phase 2 clinical trial, AM-111 showed
a favorable safety profile. Furthermore, in patients with severe to profound ASNHL, we observed a clinically relevant improvement
in hearing threshold, speech discrimination and a higher rate of complete tinnitus remission compared with placebo. We intend to
conduct two pivotal Phase 3 trials in the treatment of idiopathic inner ear hearing loss, or ISSNHL, a subset of ASNHL, titled
Efficacy and Safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss, or HEALOS, and Efficacy and Safety of AM-111 as
Acute Sudden Sensorineural Hearing Loss Treatment, or ASSENT. HEALOS has commenced enrollment in Europe and Asia and we intend
to initiate ASSENT in the U.S., Canada and South Korea in mid-2016. In addition, we plan to conduct a Phase 2 trial in the treatment
of surgery-induced hearing loss titled Efficacy and Safety of AM-111 in the Treatment of Surgery-Induced Hearing Loss, or REACH,
in the U.S. Provided that we obtain grant or other funding, REACH could be initiated in the first half of 2017 at the earliest.
We believe that, if approved, AM-111 could become the first approved pharmaceutical treatment for ASNHL. AM-111 received orphan
drug designation for the treatment of ASNHL from both the FDA and the EMA.
The following table summarizes our product
development pipeline:
_______________
(1) Dates of key milestones are indicative
and subject to change.
|
Strengths
We believe we are a leader in the development
of novel therapeutic products for inner ear disorders due to several factors.
·
First mover advantage.
With two product candidates in late stage clinical development, we believe we are currently the clinically most advanced company
working on inner ear therapeutics. We believe that AM-101 and AM-111 are the only drug candidates that have demonstrated positive
efficacy in randomized placebo-controlled clinical trials in acute inner ear tinnitus and acute inner ear hearing loss. As a result,
we believe we will be the first to market with FDA or EMA-approved products for these indications.
·
Barriers
to entry.
Our products are protected not only through intellectual property rights but also potentially by the orphan
drug status granted to AM-111 as well as by the know-how across several disciplines that is required to formulate and reliably
deliver drugs to the inner ear. Our proprietary gel formulation, its manufacturing and its application are part of our intellectual
property, know-how and competitive advantage. In addition, we believe that our intellectual property broadly directed to polymer-based
formulations for the treatment of middle or inner ear disorders will serve as barriers to entry beyond our current products.
·
Efficient commercialization.
Given that the market for our therapeutic product candidates
can be efficiently accessed through a limited number of specialist ENT physicians and specialist neurotologists, we intend to
build our own sales force in order to commercialize these products in the United States and key European markets.
·
Experienced management.
Having been focused on developing therapeutic products for
inner ear indications for over a decade, we believe that our senior management provides us with significant capabilities. Our
Chief Executive Officer and founder, Thomas Meyer, has played several pivotal roles in our development and evolution. Prior to
Auris Medical, he was the CEO of Disetronic, a fast growing Swiss diabetes care company sold to Roche in 2003. Other key members
of our management team bring significant experience in clinical, product and business development in biopharmaceutical companies.
Strategy
Our goal is to become the leading biopharmaceutical
company focused on developing and commercializing novel therapeutics to treat inner ear disorders. The key elements of our strategy
to achieve this goal are:
·
Target inner ear disorders that have a defined pathophysiology and that are amenable to treatment.
We are
focusing on inner ear disorders for which the pathophysiology is well characterized, can be effectively targeted and where affected
patients seek medical attention proactively.
·
Use drug delivery techniques and proprietary drug formulations for effective, safe and rapid local administration
to the inner ear.
We are developing treatments for inner ear disorders based on intratympanic injections into the middle
ear. This short outpatient procedure allows us to deliver therapeutic concentrations of drug in a highly targeted fashion with
only minimal systemic exposure. We are using proprietary, fully biocompatible and biodegradable gel formulations for optimum middle
ear tolerance and effective diffusion of active substances into the inner ear.
·
Bring AM-101 and AM-111 to market.
We plan to focus most of our resources on the development and commercialization of
our two lead product candidates. AM-101 is in two Phase 3 clinical trials, based on an SPA with the FDA and guidance from
the EMA. We expect to have top-line results from the first Phase 3 trial for AM-101 in the third quarter of 2016, with
results for the second trial following in a few months later. We intend to conduct two pivotal Phase 3 trials with AM-111 in
the treatment of ISSNHL, titled HEALOS and ASSENT. HEALOS, has commenced enrollment in Europe and Asia and we intend to
initiate ASSENT in the U.S., Canada and South Korea in mid-2016. In addition, we are planning a Phase 2
|
trial titled REACH in order to test
AM-111 in the treatment of surgery-induced hearing loss. Provided we obtain grant or other funding for REACH, REACH could be initiated
in the first half 2017.
·
Build an efficient commercial infrastructure to maximize the value of our product candidates.
We intend to
build commercial operations in the North American market and in select European markets. In those markets, we expect our commercial
operations to include specialty sales forces targeting ENTs and specialists in neurotology both in hospitals and in private practice.
In other markets, we expect to seek partnerships that would maximize our products’ commercial potential.
·
Expand our pipeline through internal development, academic collaborations, in-licensing and acquisitions.
Through
our work with academic research partners on the pathophysiology of tinnitus and hearing loss and clinical development we have
gained novel insights that will help us both to create new pipeline products that act by way of novel mechanisms as well as to
expand the therapeutic focus for our existing product candidates beyond their current indications. We plan to further maximize
our commercial potential through product life cycle management, and with licensing or acquisition of compounds that could augment
our product offering in ENT disorders.
Risk Factors
An investment in our common shares involves
risk. You should carefully consider the information set forth in the section of this prospectus supplement entitled “Risk
Factors” beginning on page S-6, as well as other information included or incorporated by reference in this prospectus supplement
and the accompanying prospectus, before deciding whether to invest in our common shares.
Other Information
We are a stock corporation organized under
the laws of Switzerland. We began our current operations in 2003. On April 22, 2014, we changed our name from Auris Medical AG
to Auris Medical Holding AG and transferred our operational business to our newly incorporated subsidiary Auris Medical AG, which
is now our main operating subsidiary. Our principal office is located at Bahnhofstrasse 21, 6300 Zug, Switzerland, telephone number
+41 41 729 71 94. We maintain a website at www.aurismedical.com where general information about us is available. Investors can
obtain copies of our filings with the Securities and Exchange Commission, or SEC, from this site free of charge, as well as from
the SEC website at www.sec.gov. We are not incorporating the contents of our website into this prospectus supplement and the accompanying
prospectus.
|
Issuer
|
Auris Medical Holding AG
|
Common shares offered by us
|
Common shares, nominal value CHF 0.40 per share, having an aggregate offering price of up to $35,000,000.
|
Manner of offering
|
“At the market offering” that may be made from time
to time through our sales agent, Cantor Fitzgerald & Co. See “Plan of Distribution” in this prospectus
supplement.
|
Use of proceeds
|
We currently intend to use the net proceeds from the sale of our common shares pursuant to the sales agreement, if any, for working capital and general corporate purposes. See “Use of Proceeds” in this prospectus supplement.
|
Risk factors
|
An investment in our common shares involves a high degree of risk. Please refer to “Risk Factors” in this prospectus supplement, “Item 3. Key Information—D. Risk factors” in our Annual Report on Form 20-F for the year ended December 31, 2015, incorporated by reference herein, and other information included or incorporated by reference in this prospectus supplement or the accompanying prospectus for a discussion of factors you should carefully consider before investing in our common shares.
|
NASDAQ Global Market symbol
|
“EARS.”
|
Risk Factors
Any investment in our common shares
involves a high degree of risk. You should carefully consider the risks described below and in “Item 3. Key Information—D.
Risk factors” in our Annual Report on Form 20-F for the year ended December 31, 2015, incorporated by reference herein and
all of the information included or incorporated by reference in this prospectus supplement and the accompanying prospectus before
deciding whether to purchase our common shares. The risks and uncertainties described below are not the only risks and uncertainties
we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our
business operations. If any of the events or circumstances described in the following risk factors actually occur, our business,
financial condition and results of operations would suffer. In that event, the price of our common shares could decline, and you
may lose all or part of your investment. The risks discussed below also include forward-looking statements and our actual results
may differ substantially from those discussed in these forward-looking statements. See “Forward-Looking Statements.”
Risks Related to this Offering and Our Common Shares
The price of our common shares may be
volatile and may fluctuate due to factors beyond our control.
The share price of publicly traded emerging
biopharmaceutical and drug discovery and development companies has been highly volatile and is likely to remain highly volatile
in the future. The market price of our common shares may fluctuate significantly due to a variety of factors, including:
|
·
|
positive or negative results of testing and clinical trials by us, strategic partners, or competitors;
|
|
·
|
delays in entering into strategic relationships with respect to development and/or commercialization of our product candidates
or entry into strategic relationships on terms that are not deemed to be favorable to us;
|
|
·
|
technological innovations or commercial product introductions by us or competitors;
|
|
·
|
changes in government regulations;
|
|
·
|
developments concerning proprietary rights, including patents and litigation matters;
|
|
·
|
public concern relating to the commercial value or safety of any of our product candidates;
|
|
·
|
financing or other corporate transactions;
|
|
·
|
publication of research reports or comments by securities or industry analysts;
|
|
·
|
general market conditions in the pharmaceutical industry or in the economy as a whole; or
|
|
·
|
other events and factors beyond our control.
|
In addition, the stock market in general
has recently experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating
performance of individual companies. Broad market and industry factors may materially affect the market price of companies’
stock, including ours, regardless of actual operating performance.
Certain principal shareholders and members
of our executive team and board of directors own a majority of our common shares and as a result will be able to exercise significant
control over us, and your interests may conflict with the interests of such shareholders.
Certain principal shareholders and their
affiliated entities as well as members of our executive team and board of directors own approximately 73.5% of our common shares.
Depending on the level of attendance at our general meetings of shareholders, these shareholders may be in a position to determine
the outcome of decisions taken at any
such general meeting. Any shareholder or group
of shareholders controlling more than 50% of the shares represented at our general meetings of shareholders may control any shareholder
resolution requiring an absolute majority of the shares represented, including the election of members to the board of directors
of our company, certain decisions relating to our capital structure, the approval of certain significant corporate transactions
and certain amendments to our articles of association. To the extent that the interests of these shareholders may differ from the
interests of the Company’s other shareholders, the latter may be disadvantaged by any action that these shareholders may
seek to pursue. Among other consequences, this concentration of ownership may have the effect of delaying or preventing a change
in control and might therefore negatively affect the market price of our common shares.
Future sales, or the possibility of future
sales, of a substantial number of our common shares could adversely affect the price of our common shares.
Future sales of a substantial number of
our common shares, or the perception that such sales will occur, could cause a decline in the market price of our common shares.
Approximately 53.0% of our common shares outstanding are held by affiliates. If these shareholders sell substantial amounts of
common shares in the public market, or the market perceives that such sales may occur, the market price of our common shares and
our ability to raise capital through an issue of equity securities could be adversely affected. We have also entered into a registration
rights agreement pursuant to which we have agreed under certain circumstances to file a registration statement to register the
resale of common shares held by certain of our shareholders, as well as to cooperate in certain public offerings of such common
shares. We have also filed registration statements to register all common shares and other equity securities that we have issued
under our prior equity incentive plans or may issue under our new omnibus equity compensation plan. These common shares may be
freely sold in the public market upon issuance, subject to certain limitations applicable to affiliates. If a large number of our
common shares are sold in the public market, the sales could reduce the trading price of our common shares and impede our ability
to raise future capital.
If you purchase the common shares sold
in this offering, you may experience immediate dilution as a result of this offering and future equity issuances.
Because the price per share of the common
shares being offered may be higher than the book value per share of our common shares, you may suffer immediate and substantial
dilution in the net tangible book value of the common shares you purchase in this offering. The issuance of additional common shares
in future offerings could be dilutive to shareholders if they do not invest in future offerings. Moreover, to the extent that we
issue options or warrants to purchase, or securities convertible into or exchangeable for, common shares in the future and those
options, warrants or other securities are exercised, converted or exchanged, shareholders may experience further dilution.
We have broad discretion in the use of
the net proceeds from this offering, if any, and may not use them effectively.
Our management has broad discretion in
the application of the net proceeds from this offering, if any, and could spend the proceeds in ways that do not improve our results
of operations or enhance the value of our common shares. The failure by our management to apply these funds effectively could result
in financial losses that could have a material adverse effect on our business, cause the price of our common shares to decline
and delay the development of our product candidates. Pending their use, we may invest the net proceeds from this offering in a
manner that does not produce income or that loses value.
We do not expect to pay dividends in
the foreseeable future.
We have not paid any dividends since our
incorporation. Even if future operations lead to significant levels of distributable profits, we currently intend that any earnings
will be reinvested in our business and that dividends will not be paid until we have an established revenue stream to support continuing
dividends. The proposal to pay future dividends to shareholders will in addition effectively be at the discretion of our board
of directors and shareholders after taking into account various factors including our business prospects, cash requirements, financial
performance and new product development. In addition, payment of future dividends is subject to certain limitation pursuant to
Swiss law or by our articles of association.
Accordingly, investors cannot rely on dividend income from our common shares and any returns on an investment in our common shares
will likely depend entirely upon any future appreciation in the price of our common shares.
We are a holding company with no material
direct operations.
We are a holding company with no material
direct operations. As a result, we would be dependent on dividends, other payments or loans from our subsidiaries in order to pay
a dividend. Our subsidiaries are subject to legal requirements of their respective jurisdictions of organization that may restrict
their paying dividends or other payments, or making loans, to us.
We are a Swiss corporation. The rights
of our shareholders may be different from the rights of shareholders in companies governed by the laws of U.S. jurisdictions.
We are a Swiss corporation. Our corporate
affairs are governed by our articles of association and by the laws governing companies incorporated in Switzerland. The rights
of our shareholders and the responsibilities of members of our board of directors may be different from the rights and obligations
of shareholders and directors of companies governed by the laws of U.S. jurisdictions. In the performance of its duties, our board
of directors is required by Swiss law to consider the interests of our company, our shareholders, our employees and other stakeholders,
in all cases with due observation of the principles of reasonableness and fairness. It is possible that some of these parties will
have interests that are different from, or in addition to, your interests as a shareholder. Swiss corporate law limits the ability
of our shareholders to challenge resolutions made or other actions taken by our board of directors in court. Our shareholders generally
are not permitted to file a suit to reverse a decision or an action taken by our board of directors but are instead only permitted
to seek damages for breaches of fiduciary duty. As a matter of Swiss law, shareholder claims against a member of our board of directors
for breach of fiduciary duty would have to be brought in Zug, Switzerland, or where the relevant member of our board of directors
is domiciled. In addition, under Swiss law, any claims by our shareholders against us must be brought exclusively in Zug, Switzerland.
Our common shares are issued under the
laws of Switzerland, which may not protect investors in a similar fashion afforded by incorporation in a U.S. state.
We are organized under the laws of Switzerland.
There can be no assurance that Swiss law will not change in the future or that it will serve to protect investors in a similar
fashion afforded under corporate law principles in the U.S., which could adversely affect the rights of investors.
U.S. shareholders may not be able to
obtain judgments or enforce civil liabilities against us or our executive officers or members of our board of directors.
We are organized under the laws of Switzerland
and our jurisdiction of incorporation is Zug, Switzerland. Moreover, a number of our directors and executive officers and a number
of directors of each of our subsidiaries are not residents of the United States, and all or a substantial portion of the assets
of such persons are located outside the United States. As a result, it may not be possible for investors to effect service of process
within the United States upon us or upon such persons or to enforce against them judgments obtained in U.S. courts, including judgments
in actions predicated upon the civil liability provisions of the federal securities laws of the United States. We have been advised
by our Swiss counsel that there is doubt as to the enforceability in Switzerland of original actions, or in actions for enforcement
of judgments of U.S. courts, of civil liabilities to the extent predicated upon the federal and state securities laws of the United
States. Original actions against persons in Switzerland based solely upon the U.S. federal or state securities laws are governed,
among other things, by the principles set forth in the Swiss Federal Act on International Private Law. This statute provides that
the application of provisions of non-Swiss law by the courts in Switzerland shall be precluded if the result is incompatible with
Swiss public policy. Also, mandatory provisions of Swiss law may be applicable regardless of any other law that would otherwise
apply.
Switzerland and the United States do not
have a treaty providing for reciprocal recognition and enforcement of judgments in civil and commercial matters. The recognition
and enforcement of a judgment of the courts of the
United States in Switzerland is governed by
the principles set forth in the Swiss Federal Act on Private International Law. This statute provides in principle that a judgment
rendered by a non-Swiss court may be enforced in Switzerland only if:
|
·
|
the non-Swiss court had jurisdiction pursuant to the Swiss Federal Act on Private International Law;
|
|
·
|
the judgment of such non-Swiss court has become final and non-appealable;
|
|
·
|
the judgment does not contravene Swiss public policy;
|
|
·
|
the court procedures and the service of documents leading to the judgment were in accordance with the due process of law; and
|
|
·
|
no proceeding involving the same position and the same subject matter was first brought in Switzerland, or adjudicated in Switzerland,
or was earlier adjudicated in a third state and this decision is recognizable in Switzerland.
|
Our status as a Swiss corporation means
that our shareholders enjoy certain rights that may limit our flexibility to raise capital, issue dividends and otherwise manage
ongoing capital needs.
Swiss law reserves for approval by shareholders
certain corporate actions over which a board of directors would have authority in some other jurisdictions. For example, the payment
of dividends and cancellation of treasury shares must be approved by shareholders. Swiss law also requires that our shareholders
themselves resolve to, or authorize our board of directors to, increase our share capital. While our shareholders may authorize
share capital that can be issued by our board of directors without additional shareholder approval, Swiss law limits this authorization
to 50% of the issued share capital at the time of the authorization. The authorization, furthermore, has a limited duration of
up to two years and must be renewed by the shareholders from time to time thereafter in order to be available for raising capital.
Additionally, Swiss law grants pre-emptive rights to existing shareholders to subscribe for new issuances of shares. In certain
circumstances, including those explicitly described in our articles of association, our board of directors may withdraw such pre-emption
rights. Shareholders who believe pre-emption rights were improperly withdrawn may sue us for damages. Swiss law also does not provide
as much flexibility in the various rights and regulations that can attach to different categories of shares as do the laws of some
other jurisdictions. These Swiss law requirements relating to our capital management may limit our flexibility, and situations
may arise where greater flexibility would have provided benefits to our shareholders.
We are a foreign private issuer and,
as a result, we are not subject to U.S. proxy rules and are subject to Exchange Act reporting obligations that, to some extent,
are more lenient and less frequent than those of a U.S. domestic public company.
We report under the Securities Exchange
Act of 1934, as amended, or the Exchange Act, as a non-U.S. company with foreign private issuer status. Because we qualify as a
foreign private issuer under the Exchange Act and although we are subject to Swiss laws and regulations with regard to such matters
and intend to furnish quarterly financial information to the SEC, we are exempt from certain provisions of the Exchange Act that
are applicable to U.S. domestic public companies, including (i) the sections of the Exchange Act regulating the solicitation of
proxies, consents or authorizations in respect of a security registered under the Exchange Act; (ii) the sections of the Exchange
Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit
from trades made in a short period of time; and (iii) the rules under the Exchange Act requiring the filing with the SEC of quarterly
reports on Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K, upon the occurrence
of specified significant events. In addition, foreign private issuers are not required to file their annual report on Form 20-F
until four months after the end of each financial year, while U.S. domestic issuers that are accelerated filers are required to
file their annual report on Form 10-K within 75 days after the end of each fiscal year. Foreign private issuers are also exempt
from the Regulation Fair Disclosure, aimed at preventing issuers from making selective disclosures of material information. As
a result of the above, you may not have the same protections afforded to shareholders of companies that are not foreign private
issuers.
As a foreign private issuer and as permitted
by the listing requirements of Nasdaq, we follow certain home country governance practices rather than the corporate governance
requirements of Nasdaq.
We are a foreign private issuer. As a result,
in accordance with Nasdaq Listing Rule 5615(a)(3), we comply with home country governance requirements and certain exemptions thereunder
rather than complying with certain of the corporate governance requirements of Nasdaq.
Swiss law does not require that a majority
of our board of directors consists of independent directors. Our board of directors therefore may include fewer independent directors
than would be required if we were subject to Nasdaq Listing Rule 5605(b)(1). In addition, we are not subject to Nasdaq Listing
Rule 5605(b)(2), which requires that independent directors regularly have scheduled meetings at which only independent directors
are present.
Although Swiss law also requires that we
adopt a compensation committee, we follow home country requirements with respect to such committee. As a result, our practice varies
from the requirements of Nasdaq Listing Rule 5605(d), which sets forth certain requirements as to the responsibilities, composition
and independence of compensation committees. In addition, in accordance with Swiss law, we have opted not to implement a standalone
nominating committee. To this extent, our practice varies from the independent director oversight of director nominations requirements
of Nasdaq Listing Rule 5605(e).
Furthermore, in accordance with Swiss law
and generally accepted business practices, our articles of association do not provide quorum requirements generally applicable
to general meetings of shareholders. Our practice thus varies from the requirement of Nasdaq Listing Rule 5620(c), which requires
an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the
outstanding voting stock. Our articles of association provide for an independent proxy holder elected by our shareholders, who
may represent our shareholders at a general meeting of shareholders, and we must provide shareholders with an agenda and other
relevant documents for the general meeting of shareholders. However, Swiss law does not have a regulatory regime for the solicitation
of proxies and company solicitation of proxies is prohibited for public companies in Switzerland, thus our practice varies from
the requirement of Nasdaq Listing Rule 5620(b), which sets forth certain requirements regarding the solicitation of proxies. In
addition, we have opted out of shareholder approval requirements for the issuance of securities in connection with certain events
such as the acquisition of stock or assets of another company, the establishment of or amendments to equity-based compensation
plans for employees, a change of control of us and certain private placements. To this extent, our practice varies from the requirements
of Nasdaq Listing Rule 5635, which generally requires an issuer to obtain shareholder approval for the issuance of securities in
connection with such events.
As a result of the above, you may not have
the same protections afforded to shareholders of companies that are not foreign private issuers.
We may lose our foreign private issuer
status, which would then require us to comply with the Exchange Act’s domestic reporting regime and cause us to incur significant
legal, accounting and other expenses.
We are a foreign private issuer and therefore
we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable
to U.S. domestic issuers. In order to maintain our current status as a foreign private issuer, either (a) a majority of our common
shares must be either directly or indirectly owned of record by non-residents of the United States or (b)(i) a majority of our
executive officers or directors may not be United States citizens or residents, (ii) more than 50 percent of our assets cannot
be located in the United States and (iii) our business must be administered principally outside the United States. These criteria
are tested on the last business day of our second fiscal quarter, each year. If we lost this status, we would be required to comply
with the Exchange Act reporting and other requirements applicable to U.S. domestic issuers, which are more detailed and extensive
than the requirements for foreign private issuers. We may also be required to make changes in our corporate governance practices
in accordance with various SEC and stock exchange rules. The regulatory and compliance costs to us under U.S. securities laws if
we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher than
the cost we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would
increase our legal and financial compliance costs and would make some activities highly time consuming and costly. We also expect
that if we were
required to comply with the rules and regulations
applicable to U.S. domestic issuers, it would make it more difficult and expensive for us to obtain director and officer liability
insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules
and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors.
We are an “emerging growth company,”
and we cannot be certain if the reduced reporting requirements applicable to “emerging growth companies” will make
our common shares less attractive to investors.
We are an “emerging growth company,”
as defined in the JOBS Act. For as long as we continue to be an “emerging growth company,” we may take advantage of
exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth
companies,” including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley
Act of 2002, exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval
of any golden parachute payments not previously approved. We could be an “emerging growth company” until 2019, although
circumstances could cause us to lose that status earlier, including if the market value of our common shares held by non-affiliates
exceeds $700 million as of any June 30 (the end of our second fiscal quarter) before that time, in which case we would no longer
be an “emerging growth company” as of the following December 31 (our fiscal year end). We cannot predict if investors
will find our common shares less attractive because we may rely on these exemptions. If some investors find our common shares less
attractive as a result, there may be a less active trading market for our common shares and the price of our common shares may
be more volatile.
If we fail to maintain an effective system
of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As
a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the
trading price of our common shares.
Effective internal controls over financial
reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures,
are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their
implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection
with Section 404 of the Sarbanes-Oxley Act of 2002, or any subsequent testing by our independent registered public accounting firm,
may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may
require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement.
Inferior internal controls could also subject us to regulatory scrutiny and sanctions, impair our ability to raise revenue and
cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price
of our common shares.
We will be required to disclose changes
made in our internal controls and procedures and our management will be required to assess the effectiveness of these controls
annually. However, for as long as we are an “emerging growth company” under the JOBS Act, our independent registered
public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant
to Section 404. We could be an “emerging growth company” until 2019. An independent assessment of the effectiveness
of our internal controls could detect problems that our management’s assessment might not. Undetected material weaknesses
in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation.
If securities or industry analysts do
not publish research, or publish inaccurate or unfavorable research, about our business, the price of our common shares and our
trading volume could decline.
The trading market for our common shares
depends in part on the research and reports that securities or industry analysts publish about us or our business. We do not have
any control over these analysts. We cannot assure you that analysts will cover us or provide favorable coverage. If one or more
of the analysts who cover us downgrade our common shares or publish inaccurate or unfavorable research about our business, the
price of our common shares would likely decline. If one or more of these analysts cease coverage of our company or fail to publish
reports on us regularly, demand for our common shares could decrease, which might cause the price of our common shares and trading
volume to decline.
We believe that we were a “passive
foreign investment company,” or PFIC, for U.S. federal income tax purposes for our 2014 and 2015 taxable years, and we expect
to be a PFIC for our current year and for the foreseeable future.
We believe that we were a “passive
foreign investment company,” or PFIC, for U.S. federal income tax purposes for our 2014 and 2015 taxable years, and we expect
to be a PFIC for our current year and for the foreseeable future. In addition, we may, directly or indirectly, hold equity interests
in other PFICs, or Lower-tier PFICs. Under the Internal Revenue Code of 1986, as amended, or the Code, we will be a PFIC for any
taxable year in which (i) 75% or more of our gross income consists of passive income or (ii) 50% or more of the average quarterly
value of our assets consists of assets that produce, or are held for the production of, passive income. For purposes of the above
calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation
is treated as if it held its proportionate share of the assets of the other corporation and received directly its proportionate
share of the income of the other corporation. Passive income generally includes dividends, interest, rents, royalties and capital
gains.
If we are a PFIC for any taxable year during
which a U.S. investor holds our shares, the U.S. investor may be subject to adverse tax consequences, including (i) the treatment
of all or a portion of any gain on disposition as ordinary income, (ii) the application of a deferred interest charge on such gain
and the receipt of certain dividends and (iii) compliance with certain reporting requirements.
For further discussion of the adverse U.S.
federal income tax consequences of our classification as a PFIC, see “Taxation—Material U.S. Federal Income Tax Consideration
for U.S. Holders.”
Use of Proceeds
The amount of proceeds from this offering
will depend upon the number of our common shares sold and the price at which they are sold. There can be no assurance that we will
be able to sell any common shares under, or fully utilize, the sales agreement with Cantor Fitzgerald & Co. as a source of
financing.
We intend to use the net proceeds from
the sale of our common shares pursuant to the sales agreement, if any, for working capital and general corporate purposes.
Market for
Our Common Shares and Dividends
Our common shares are quoted on the NASDAQ
Global Market under the symbol “EARS.” The following table sets forth on a per share basis the low and high closing
sale prices of our common shares as reported by the NASDAQ Global Market for the periods presented.
|
High
|
Low
|
Year Ended:
|
|
|
December 31, 2014 (starting August 6, 2014)
|
7.23
|
3.51
|
December 31, 2015
|
6.38
|
3.02
|
Year Ended December 31, 2014:
|
|
|
Third Quarter (starting August 6, 2014)
|
7.23
|
5.37
|
Fourth Quarter
|
5.75
|
3.51
|
Year Ended December 31, 2015:
|
|
|
First Quarter
|
6.38
|
3.51
|
Second Quarter
|
6.05
|
4.33
|
Third Quarter
|
5.56
|
3.50
|
Fourth Quarter
|
5.00
|
3.02
|
Month Ended:
|
|
|
November 30, 2015
|
3.88
|
3.02
|
December 31, 2015
|
5.00
|
3.09
|
January 31, 2016
|
7.79
|
4.13
|
February 29, 2016
|
4.75
|
3.91
|
March 31, 2016
|
4.79
|
3.36
|
April 30, 2016
|
4.33
|
3.61
|
May 2016 (through May 26, 2016)
|
3.64
|
3.13
|
As of May 26, 2016, we had 34,329,704 common
shares issued and outstanding held by 14 registered holders, one of which is Cede & Co., a nominee for The Depository Trust
Company (“DTC”). All of the common shares held by brokerage firms, banks and other financial institutions as nominees
for beneficial owners are deposited into participant accounts at DTC and therefore are considered to be held of record by Cede
& Co. as one shareholder.
We have never paid a dividend, and we do
not anticipate paying dividends in the foreseeable future. We intend to retain all available funds and any future earnings to fund
the development and expansion of our business. As a result, investors in our common shares will benefit in the foreseeable future
only if our common shares appreciate in value.
Under Swiss law, any dividend must be proposed
by our board of directors and approved by a shareholders’ meeting. In addition, our auditors must confirm that the dividend
proposal of our board of directors conforms to Swiss statutory law and our articles of incorporation. A Swiss corporation may pay
dividends only if it has sufficient distributable profits brought forward from the previous business years (“
Gewinnvortrag
”)
or if it has distributable reserves (“
frei verfügbare Reserven
”), each as evidenced by its audited standalone
statutory balance sheet prepared pursuant to Swiss law and after allocations to reserves required by Swiss law and its articles
of association have been deducted. Distributable reserves are generally booked either as “free reserves” (“
freie
Reserven
”) or as “reserve from capital contributions” (“
Reserven aus Kapitaleinlagen
”).
Distributions out of issued share capital, which is the aggregate nominal value of a corporation’s issued shares, may be
made only by way of a share capital reduction.
We are a holding company with no material
direct operations. As a result, we would be dependent on dividends, other payments or loans from our subsidiaries in order to pay
a dividend. Our subsidiaries are subject to legal requirements of their respective jurisdictions of organization that may restrict
their paying dividends or other payments, or making loans, to us.
Capitalization
The table below sets forth our cash and
cash equivalents and our total capitalization (defined as total debt and shareholders’ equity) as of March 31, 2016, derived
from our unaudited consolidated interim financial statements, prepared in accordance with IFRS and incorporated by reference in
this prospectus supplement:
|
·
|
on an actual basis; and
|
|
·
|
on an as adjusted basis to give effect to our issuance and sale of $35,000,000 of common shares in this offering, at the assumed
public offering price of $3.37 per common share, which is the last reported sale price of our common shares on the Nasdaq Global
Market on May 26, 2016, after deducting commissions and estimated offering expenses payable by us.
|
The as adjusted information is illustrative
only and will adjust based on the actual price to the public, the actual number of common shares sold and other terms of the offering
determined at the time our common shares are sold pursuant to this prospectus supplement. Investors should read this table in conjunction
with our audited consolidated financial statements and our unaudited consolidated interim financial statements and management’s
discussion and analysis thereon, each as incorporated by reference into this prospectus supplement.
Swiss Franc amounts have been translated into U.S. dollars at a rate of CHF 0.9583 to USD 1.00, the official exchange rate
quoted as of March 31, 2016 by the U.S. Federal Reserve Bank. Such U.S. dollar amounts are not necessarily indicative of the
amounts of U.S. dollars that could actually have been purchased upon exchange of Swiss Francs on March 31, 2016 and have been
provided solely for the convenience of the reader.
|
March
31, 2016
|
|
Actual
|
As
Adjusted
|
|
(in thousands of CHF except share
and per share data)
|
Cash and cash equivalents (1)
|
41,393
|
73,412
|
Total debt
|
—
|
—
|
Shareholders’ equity:
|
|
|
Share capital
|
|
|
Common shares, nominal value CHF 0.40 per share; 34,329,704 shares issued and outstanding on an actual basis; 44,715,460 shares issued and outstanding on an adjusted basis
|
13,732
|
17,886
|
Share premium
|
112,841
|
140,706
|
Foreign currency translation reserve
|
(22)
|
(22)
|
Accumulated deficit
|
(90,659)
|
(90,659)
|
Total shareholders’ equity attributable to owners of the company (1)
|
35,892
|
67,911
|
Total capitalization (1)
|
35,892
|
67,911
|
_______________
|
(1)
|
As adjusted cash and cash equivalents represents actual cash and cash equivalents plus the assumed net proceeds of this offering.
|
Dilution
If you invest in our common shares, your
interest will be diluted to the extent of the difference between the price you pay in this offering and the as adjusted net tangible
book value per common share after this offering.
As of March 31, 2016, we had a net tangible
book value of $35.9 million, corresponding to a net tangible book value of $1.05 per common share. Net tangible book value per
share represents the amount of our total assets less our total liabilities, excluding intangible assets, divided by 34,329,704,
the total number of our common shares outstanding as of March 31, 2016.
After giving effect to the assumed sale
by us of $35,000,000 of our common shares at the assumed offering price of $3.37 per common share, which is the last reported sale
price of our common shares on the Nasdaq Global Market on May 26, 2016, after deducting commissions and estimated offering expenses
payable by us, our as adjusted net tangible book value estimated as of March 31, 2016 would have been approximately $69.3 million,
representing $1.55 per common share. This represents an immediate increase in net tangible book value of $0.50 per common share
to existing shareholders and an immediate dilution in net tangible book value of $1.82 per common share to new investors purchasing
common shares in this offering. Dilution for this purpose represents the difference between the price per common share paid by
these purchasers and net tangible book value per common share immediately after the completion of the offering. The as adjusted
information is illustrative only and will adjust based on the actual price to the public, the actual number of common shares sold
and other terms of the offering determined at the time our common shares are sold pursuant to this prospectus supplement.
The following table illustrates this dilution
to new investors purchasing common shares in the offering.
Assumed public offering price per share
|
$3.37
|
Net tangible book value per common share as of March 31, 2016
|
$1.05
|
Increase in net tangible book value per common share attributable to new investors
|
$0.50
|
As adjusted net tangible book value per common share after the offering
|
$1.55
|
Dilution per common share to new investors
|
$1.82
|
Percentage of dilution in net tangible book value per common share for new investors
|
54.0%
|
The above discussion and tables are based
on our actual common shares outstanding as of March 31, 2016 on an as adjusted basis and excludes 770,796 of our common shares
available for issuance pursuant to our conditional share capital for equity incentive plans under our amended and restated articles
of association and 629,010 of our common shares issuable upon the exercise of options outstanding as of March 31, 2016 at a weighted
average exercise price of $4.99 per common share.
To the extent that outstanding options
are exercised, you may experience further dilution. In addition, we may choose to raise additional capital due to market conditions
or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent
that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities may
result in further dilution to our shareholders.
Swiss Franc amounts have been translated
into U.S. dollars at a rate of CHF 0.9583 to USD 1.00, the official exchange rate quoted as of March 31, 2016 by the U.S. Federal
Reserve Bank. Such U.S. dollar amounts are not necessarily indicative of the amounts of U.S. dollars that could actually have been
purchased upon exchange of Swiss Francs on March 31, 2016 and have been provided solely for the convenience of the reader.
Description
of Share Capital and Articles of Association
The Company
We
are a Swiss stock corporation (
Aktiengesellschaft
) organized under the laws of Switzerland. We were formed in 1998 and started operations as Auris Medical in 2003.
We are currently registered in Zug, Switzerland. Our head office is currently located at Bahnhofstrasse 21, 6300 Zug,
Switzerland.
Share Capital
As of
May 26, 2016, our issued fully
paid-in share capital consists of CHF 13,731,881.60, divided into 34,329,704 common shares with a nominal value of CHF 0.40 each
and no preferred shares.
Articles of Association
When
we refer to our articles of association in this prospectus, we refer to our amended and restated articles of association dated
as of April 8, 2016.
Ordinary Capital Increase, Authorized
and Conditional Share Capital
Under Swiss law, we may increase our share
capital (
Aktienkapital
) with a resolution of the general meeting of shareholders (ordinary capital increase) that must be
carried out by the board of directors within three months in order to become effective. In the case of subscription and increase
against payment of contributions in cash, a resolution passed by an absolute majority of the shares represented at the general
meeting of shareholders is required. In the case of subscription and increase against contributions in kind or to fund acquisitions
in kind, when shareholders’ statutory pre-emptive rights are withdrawn or where transformation of reserves into share capital
is involved, a resolution passed by two-thirds of the shares represented at a general meeting of shareholders and the absolute
majority of the nominal amount of the shares represented is required.
Our shareholders, by a resolution passed
by two-thirds of the shares represented at a general meeting of shareholders and the absolute majority of the nominal amount of
the shares represented, may empower our board of directors to issue shares of a specific aggregate nominal amount up to a maximum
of 50% of the share capital in the form of:
|
·
|
conditional capital (
bedingtes Kapital
) for the purpose of issuing shares in connection with, among other things, (i)
option and conversion rights granted in connection with warrants and convertible bonds issued by the Company or one of our subsidiaries
or (ii) grants of rights to employees, members of our board of directors or consultants or our subsidiaries to subscribe for new
shares (conversion or option rights); and/or
|
|
·
|
authorized capital (
genehmigtes Kapital
) to be utilized by the board of directors within a period determined by the
shareholders but not exceeding two years from the date of the shareholder approval.
|
Pre-emptive Rights
Pursuant to the Swiss Code of Obligations,
or CO, shareholders have pre-emptive rights (
Bezugsrechte
) to subscribe for new issuances of shares. With respect to conditional
capital in connection with the issuance of conversion rights, convertible bonds or similar debt instruments, shareholders have
advance subscription rights (
Vorwegzeichnungsrechte
) for the subscription of conversion rights, convertible bonds or similar
debt instruments.
A resolution passed at a general meeting
of shareholders by two-thirds of the shares represented and the absolute majority of the nominal value of the shares represented
may authorize our board of directors to withdraw or limit pre-emptive rights and/or advance subscription rights in certain circumstances.
If pre-emptive rights are granted, but
not exercised, the board of directors may allocate the pre-emptive rights as it elects.
With respect to our authorized share capital,
the board of directors is authorized by our articles of association to withdraw or to limit the pre-emptive rights of shareholders,
and to allocate them to third parties or to us, in the event that the newly issued shares are used for a purpose set forth in our
articles of association.
Our Authorized Share Capital
At our ordinary general meeting of
shareholders dated April 8, 2016, the shareholders approved an amendment to our authorized share capital. The new provision
(article 3a of the articles of association) reads as follows (translation of the binding original German version):
“
The Board of Directors is authorized
at any time until 8 April 2018 to increase the share capital by a maximum aggregate amount of CHF 6,860,000.00 through the
issuance of not more than 17,150,000 registered shares, which will have to be fully paid-in, with a nominal value of CHF 0.40
each.
Increases in partial amounts are permitted.
The Board of Directors may issue new shares also by means of underwriting or in any other manner by one or more banks and subsequent
offer to shareholders or third parties. The Board of Directors determines the type of contributions, the issue price, the time
of the issue, the conditions for the exercise of the pre-emptive rights, the allocation of pre-emptive rights which have not been
exercised, and the date on which the dividend entitlement starts. The Board of Directors is authorized to permit, to restrict or
to deny the trade with pre-emptive rights.
If pre-emptive rights are granted, but
not exercised, the Board of Directors may use the respective shares in the interest of the Corporation.
The Board of Directors is authorized
to restrict or to exclude the pre-emptive rights of the shareholders, and to allocate them to third parties or to the Corporation,
in the event of use of the shares for the purpose of: a) expanding the shareholder base in certain capital markets or in the context
of the listing, admission to official trading or registration of the shares at domestic or international stock exchanges; b) granting
an over-allotment option (“greenshoe”) to one or several underwriters in connection with a placement of shares; c)
share placements, provided the issue price is determined by reference to the market price; d) the participation of employees, Members
of the Board of Directors or consultants of the Corporation or of one of its Group companies according to one or several equity
incentive plans issued by the Board of Directors; e) the acquisition of companies, company assets, participations, the acquisition
of products, intellectual property rights, licenses or new investment projects or for public or private share placements for the
financing and/or refinancing of such transactions; f) for raising equity capital in a fast and flexible manner as such transaction
would be difficult to carry out, or could be carried out only at less favorable terms, without the exclusion of the pre-emptive
rights of the existing shareholders; or g) the acquisition of a participation in the Corporation by a strategic partner (including
in the case of a public takeover offer).
”
Within the limits of Swiss law, the general
meeting of shareholders may increase or alter the authorization granted to the board of directors. See “—Ordinary Capital Increase, Authorized and Conditional Share Capital.”
On May 5, 2016, the Company’s board
of directors approved the use of our authorized share capital, allowing the issuance and transfer of new common shares in connection
with the offering described in this prospectus supplement. To effect any capital increase based on our authorized share capital
in connection with the offering, the Company will have to follow the relevant procedures under Swiss law. In particular, the Company’s
board of directors will have to approve a general authorization resolution (
Ermächtigungsbeschluss
), issue a capital
increase report (
Kapitalerhöhungsbericht
), approve a notarized confirmation resolution (
Feststellungsbeschluss
)
on the capital increase and the amended articles of association, and obtain (i) duly executed subscription form(s) covering the
subscription of the relevant number of new shares, (ii) a report of an audit firm relating to the withdrawal of the pre-emptive
rights, as well as (iii) a banking confirmation confirming the payment of the aggregate nominal value of the respective number
of new shares to a special Swiss bank account, all in accordance with Swiss law. The Company’s board of directors will subsequently
have to file the relevant documentation accompanied by an application form with the competent commercial register. Any issuance
of common shares based on such filing(s) is
subject to the recording of the respective
capital increase(s) in the commercial register in accordance with Swiss law.
Our Conditional Share Capital
Conditional Share Capital for Warrants and
Convertible Bonds
At our ordinary general meeting of shareholders
dated April 8, 2016, the shareholders approved an amendment to our conditional share capital for financing purposes. The new provision
(article 3b of the articles of association) reads as follows (translation of the binding original German version):
“
The Corporation’s share
capital shall be increased by a maximum aggregate amount of CHF 4,860,000.00 through the issuance of not more than 12,150,000
registered shares, which will have to be fully paid-in, with a nominal value of CHF 0.40 each, by the exercise of option and
conversion rights which are granted in connection with bonds, similar obligations, loans or other financial market instruments
or contractual obligations of the Corporation or one of its Group companies, and/or by the exercise of option rights issued by
the Corporation or one of its Group companies (“Financial Instruments”). The pre-emptive rights of shareholders are
excluded. The holders of Financial Instruments are entitled to the new shares. The conditions of the Financial Instruments shall
be determined by the Board of Directors.
When issuing Financial Instruments the
Board of Directors is authorized to limit or exclude the advance subscription rights of shareholders:
|
a)
|
for the purpose of financing or refinancing the acquisition of enterprises, divisions thereof, or of participations, products,
intellectual property rights, licenses, cooperations or of newly planned investments of the Corporation;
|
|
b)
|
if the issue occurs on domestic or international capital markets including private placements; or
|
|
c)
|
for purposes of an underwriting of the Financial Instruments by a banking institution or a consortium of banks with subsequent
offering to the public.
|
To the extent that the advance subscription
rights are excluded, i) the Financial Instruments are to be placed at market conditions; ii) the exercise period, the conversion
period or the exchange period of the Financial Instruments may not exceed 10 years as of the date of the issue; and iii) the conversion
price, the exchange price or other exercise price of the Financial Instruments must be determined by reference to the market price
.”
Conditional Share Capital for Equity Incentive
Plans
At our ordinary general meeting of shareholders
dated April 8, 2016, the shareholders approved an amendment to our conditional share capital for equity incentive plans. The new
provision (last paragraph of article 3b of the articles of association) reads as follows (translation of the binding original German
version):
“
The Corporation’s share
capital shall, to the exclusion of the pre-emptive rights and advance subscription rights of shareholders, be increased by a maximum
aggregate amount of CHF 2,000,000.00 through the issuance of not more than 5,000,000 registered shares, which shall be fully
paid-in, with a nominal value of CHF 0.40 each, by issuance of shares upon the exercise of options or pre-emptive rights thereof,
which have been issued or granted to employees, Members of the Board of Directors or consultants of the Corporation or of one of
its Group companies according to one or several equity incentive plans or regulations issued by the Board of Directors. The details
shall be determined by the Board of Directors
.”
Of this amount, CHF 1,719,204, or 4,298,010
common shares, remains available, taking into account all options granted as of the date of this prospectus.
Uncertificated Securities
Our shares are uncertificated securities
(
Wertrechte
, within the meaning of art. 973c of the CO) and, when administered by a financial intermediary (
Verwahrungsstelle
,
within the meaning of the Federal Act on Intermediated Securities, “FISA”), qualify as intermediated securities (
Bucheffekten
,
within the meaning of the FISA). In accordance with art. 973c of the CO, we maintain a non-public register of uncertificated securities
(
Wertrechtebuch
). We may at any time convert uncertificated securities into share certificates (including global certificates),
one kind of certificate into another, or share certificates (including global certificates) into uncertificated securities. If
registered in our share register, a shareholder may at any time request from us a written confirmation in respect of the shares.
Shareholders are not entitled, however, to request the printing and delivery of certificates.
Participation certificates and profit
sharing certificates
The Company has not issued any non-voting
equity securities, such as participation certificates (
Partizipationsscheine
) or profit sharing certificates (
Genussscheine
),
nor has it issued any preference shares (
Vorzugsaktien
).
General Meeting of Shareholders
Ordinary/extraordinary meetings and powers
The general meeting of shareholders is
our supreme corporate body. Under Swiss law, ordinary and extraordinary general meetings of shareholders may be held. Under Swiss
law, an ordinary general meeting of shareholders must be held annually within six months after the end of a corporation’s
financial year. In our case, this means on or before June 30.
The following powers are vested exclusively
in the general meeting of shareholders:
|
·
|
adopting and amending our articles of association;
|
|
·
|
electing the members of the board of directors, the chairman of the board of directors, the members of the compensation committee,
the auditors and the independent proxy;
|
|
·
|
approving the annual report, the annual statutory financial statements and the consolidated financial statements, and deciding
on the allocation of profits as shown on the balance sheet, in particular with regard to dividends and bonus payments to members
of the board of directors;
|
|
·
|
approving the compensation of members of the board of directors and executive management, which under Swiss law is not necessarily
limited to the executive officers;
|
|
·
|
discharging the members of the board of directors and executive management from liability with respect to their tenure in the
previous financial year;
|
|
·
|
dissolving the Company with or without liquidation;
|
|
·
|
deciding matters reserved to the general meeting of shareholders by law or our articles of association or that are presented
to it by the board of directors.
|
An extraordinary general meeting of shareholders
may be called by a resolution of the board of directors or, under certain circumstances, by the Company’s auditor, liquidator
or the representatives of convertible bond holders, if any. In addition, the board of directors is required to convene an extraordinary
general meeting of shareholders if shareholders representing at least ten percent of the share capital request such general meeting
of shareholders in writing. Such request must set forth the items to be discussed and the proposals to be acted upon. The board
of directors must convene an extraordinary general meeting of shareholders and propose financial restructuring
measures if, based on the Company’s
stand-alone annual statutory balance sheet, half of our share capital and reserves are not covered by our assets.
Voting and Quorum Requirements
Shareholder resolutions and elections (including
elections of members of the board of directors) require the affirmative vote of the absolute majority of shares represented at
the general meeting of shareholders, unless otherwise stipulated by law.
A resolution of the general meeting of
the shareholders passed by two-thirds of the shares represented at the meeting, and the absolute majority of the nominal value
of the shares represented is required for:
|
·
|
amending the Company’s corporate purpose;
|
|
·
|
creating or cancelling shares with preference rights or amending rights attached to such shares;
|
|
·
|
cancelling or amending the transfer restrictions of registered shares;
|
|
·
|
creating authorized or conditional share capital;
|
|
·
|
increasing the share capital out of equity, against contributions in kind or for the purpose of acquiring specific assets and
granting specific benefits;
|
|
·
|
limiting or suppressing shareholder’s pre-emptive rights;
|
|
·
|
dissolving or liquidating the Company.
|
The same voting requirements apply to resolutions
regarding transactions among corporations based on Switzerland’s Federal Act on Mergers, Demergers, Transformations and the
Transfer of Assets, or the Merger Act (including a merger, demerger or conversion of a corporation) see “—Compulsory
Acquisitions; Appraisal Rights.”
In accordance with Swiss law and generally
accepted business practices, our articles of association do not provide quorum requirements generally applicable to general meetings
of shareholders. To this extent, our practice varies from the requirement of Nasdaq Listing Rule 5620(c), which requires an issuer
to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding
voting stock.
Notice
General meetings of shareholders must be
convened by the board of directors at least twenty days before the date of the meeting. The general meeting of shareholders is
convened by way of a notice appearing in our official publication medium, currently the Swiss Official Gazette of Commerce. Registered
shareholders may also be informed by ordinary mail. The notice of a general meeting of shareholders must state the items on the
agenda, the proposals to be acted upon and, in case of elections, the names of the nominated candidates. Except in the limited
circumstances listed below, a resolution may not be passed at a general meeting without proper notice. This limitation does not
apply to proposals to convene an extraordinary general meeting of shareholders or to initiate a special investigation. No previous
notification is required for proposals concerning items included in the agenda or for debates that do not result in a vote. The
notice period for a general meeting of shareholders may be waived if all shareholders are present or represented at such meeting.
Agenda Requests
Pursuant to Swiss law, one or more shareholders
whose combined shareholdings represent the lower of (i) one tenth of the share capital or (ii) an aggregate nominal value of at
least CHF 1,000,000, may request that an item be included in the agenda for an ordinary general meeting of shareholders. To be
timely, the shareholder’s request must
be received by us at least 45 calendar days
in advance of the meeting. The request must be made in writing and contain, for each of the agenda items, the following information:
|
·
|
a brief description of the business desired to be brought before the ordinary general meeting of shareholders and the reasons
for conducting such business at the ordinary general meeting of shareholders;
|
|
·
|
the name and address, as they appear in the share register, of the shareholder proposing such business; and
|
|
·
|
all other information required under the applicable laws and stock exchange rules.
|
Our business report, the compensation report
and the auditor’s report must be made available for inspection by the shareholders at our registered office no later than
20 days prior to the general meeting of shareholders. Shareholders of record may be notified of this in writing.
Voting Rights
Each of our shares entitles a holder to
one vote, regardless of its nominal value. The shares are not divisible. The right to vote and the other rights of share ownership
may only be exercised by shareholders (including any nominees) or usufructuaries who are entered in our share register at cut-off
date determined by the board of directors. Those entitled to vote in the general meeting of shareholders may be represented by
the independent proxy holder (annually elected by the general meeting of shareholders), another registered shareholder or third
person with written authorization to act as proxy or the shareholder’s legal representative. The chairman has the power to
decide whether to recognize a power of attorney.
Dividends and Other Distributions
Our board of directors may propose to shareholders
that a dividend or other distribution be paid but cannot itself authorize the distribution. Dividend payments require a resolution
passed by an absolute majority of the shares represented at a general meeting of shareholders. In addition, our auditors must confirm
that the dividend proposal of our board of directors conforms to Swiss statutory law and our articles of association.
Under Swiss law, we may pay dividends only
if we have sufficient distributable profits brought forward from the previous business years (
Gewinnvortrag
), or if we have
distributable reserves (
frei verfügbare Reserven
), each as evidenced by our audited stand-alone statutory balance sheet
prepared pursuant to Swiss law, and after allocations to reserves required by Swiss law and the articles of association have been
deducted. We are not permitted to pay interim dividends out of profit of the current business year.
Distributable reserves are generally booked
either as “free reserves” (
freie Reserven
) or as “reserve from capital contributions” (
Reserven
aus Kapitaleinlagen
). Under the CO, if our general reserves (
allgemeine Reserve
) amount to less than 20% of our share
capital recorded in the commercial register (i.e., 20% of the aggregate nominal value of our issued capital), then at least 5%
of our annual profit must be retained as general reserves. The CO permits us to accrue additional general reserves. Further, a
purchase of our own shares (whether by us or a subsidiary) reduces the distributable reserves in an amount corresponding to the
purchase price of such own shares. Finally, the CO under certain circumstances requires the creation of revaluation reserves which
are not distributable.
Distributions out of issued share capital
(i.e. the aggregate nominal value of our issued shares) are not allowed and may be made only by way of a share capital reduction.
Such a capital reduction requires a resolution passed by an absolute majority of the shares represented at a general meeting of
shareholders. The resolution of the shareholders must be recorded in a public deed and a special audit report must confirm that
claims of our creditors remain fully covered despite the reduction in the share capital recorded in the commercial register. The
share capital may be reduced below CHF 100,000 only if and to the extent that at the same time the statutory minimum share capital
of CHF 100,000 is reestablished by sufficient new fully paid-up capital. Upon approval by the general meeting of shareholders of
the capital reduction, the board of directors must give public notice of the capital reduction resolution in the Swiss Official
Gazette of Commerce three times and notify creditors that they may request, within two months of the third publication, satisfaction
of or security for their claims. The reduction of the share capital may be implemented only after expiration of this time limit.
Our board of directors determines the date
on which the dividend entitlement starts. Dividends are usually due and payable shortly after the shareholders have passed the
resolution approving the payment, but shareholders may also resolve at the ordinary general meeting of shareholders to pay dividends
in quarterly or other installments.
Transfer of Shares
Shares in uncertificated form (
Wertrechte
)
may only be transferred by way of assignment. Shares that constitute intermediated securities (
Bucheffekten
) may only be
transferred when a credit of the relevant intermediated securities to the acquirer’s securities account is made in accordance
with the relevant provisions of the FISA. Article 4 of our articles of association provides that in the case of securities held
with an intermediary such as a registrar, transfer agent, trust corporation, bank or similar entity, any transfer, grant of a security
interest or usufructuary right in such intermediated securities and the appurtenant rights associated therewith requires the cooperation
of the intermediary in order for such transfer, grant of a security interest or usufructuary right to be valid against us.
Voting rights may be exercised only after
a shareholder has been entered in our share register (
Aktienbuch
) with his or her name and address (in the case of legal
entities, the registered office) as a shareholder with voting rights. Any acquirer of our shares who is not registered in our share
register as a shareholder with voting rights will still be entitled to dividends and other rights with financial value with respect
to such shares.
Inspection of Books and Records
Under the CO, a shareholder has a right
to inspect our share register with respect to his own shares and otherwise to the extent necessary to exercise his shareholder
rights. No other person has a right to inspect our share register. Our books and correspondence may be inspected with the express
authorization of the general meeting of shareholders or by resolution of the board of directors and subject to the safeguarding
of our business secrets.
Special Investigation
If the shareholders’ inspection rights
as outlined above prove to be insufficient in the judgment of the shareholder, any shareholder may propose to the general meeting
of shareholders that specific facts be examined by a special commissioner in a special investigation. If the general meeting of
shareholders approves the proposal, we or any shareholder may, within 30 calendar days after the general meeting of shareholders,
request a court in Zug, Switzerland, our registered office, to appoint a special commissioner. If the general meeting of shareholders
rejects the request, one or more shareholders representing at least 10 percent of the share capital or holders of shares in an
aggregate nominal value of at least CHF 2,000,000 may request that the court appoint a special commissioner. The court will issue
such an order if the petitioners can demonstrate that the board of directors, any member of the board of directors or our executive
management infringed the law or our articles of association and thereby caused damages to the Company or the shareholders. The
costs of the investigation would generally be allocated to us and only in exceptional cases to the petitioners.
Compulsory Acquisitions; Appraisal Rights
Business combinations and other transactions
that are governed by the Swiss Merger Act (i.e. mergers, demergers, transformations and certain asset transfers) are binding on
all shareholders. A statutory merger or demerger requires approval of two-thirds of the shares represented at a general meeting
of shareholders and the absolute majority of the nominal value of the shares represented.
Swiss corporations may be acquired by an
acquirer through the direct acquisition of the share capital of the Swiss corporation. The Swiss Merger Act provides for the possibility
of a so-called “cash-out” or “squeeze-out” merger if the acquirer controls 90% of the outstanding shares.
In these limited circumstances, minority shareholders of the corporation being acquired may be compensated in a form other than
through shares of the acquiring corporation (for instance, through cash or securities of a parent corporation of the acquiring
corporation or of another corporation). Following a statutory merger or demerger, pursuant to the Merger Act, shareholders can
file an appraisal action against the surviving company. If the consideration is deemed inadequate, the court will determine an
adequate compensation payment.
In addition, under Swiss law, the sale
of “all or substantially all of our assets” by us may require the approval of two-thirds of the number of shares represented
at a general meeting shareholders and the absolute majority of the nominal value of the shares represented. Whether a shareholder
resolution is required depends on the particular transaction, including whether the following test is satisfied:
|
·
|
a core part of the Company’s business is sold without which it is economically impracticable or unreasonable to continue
to operate the remaining business;
|
|
·
|
the Company’s assets, after the divestment, are not invested in accordance with the Company’s statutory business
purpose; and
|
|
·
|
the proceeds of the divestment are not earmarked for reinvestment in accordance with the Company’s business purpose but,
instead, are intended for distribution to the Company’s shareholders or for financial investments unrelated to the Company’s
business.
|
Board of Directors
Our articles of association provide that
the board of directors shall consist of at least three and not more than nine members.
The members of the board of directors and
the chairman are elected annually by the general meeting of shareholders for a period until the completion of the subsequent ordinary
general meeting of shareholders and are eligible for re-election. Each member of the board of directors must be elected individually.
Unless an exception is granted by the general meeting of shareholders, only persons who have not completed their seventy-fifth
year of age on the election date are eligible for election.
Powers
The board of directors has the following
non-delegable and inalienable powers and duties:
|
·
|
the ultimate direction of the business of the Company and issuing of the relevant directives;
|
|
·
|
laying down the organization of the Company;
|
|
·
|
formulating accounting procedures, financial controls and financial planning, to the extent required for the governance of
the Company;
|
|
·
|
nominating and removing persons entrusted with the management and representation of the Company and regulating the power to
sign for the Company;
|
|
·
|
the ultimate supervision of those persons entrusted with management of the Company, with particular regard to adherence to
law, our articles of association, and regulations and directives of the Company;
|
|
·
|
issuing the annual report and the compensation report, and preparing for the general meeting of shareholders and carrying out
its resolutions; and
|
|
·
|
informing the court in case of over-indebtedness.
|
The board of directors may, while retaining
such non-delegable and inalienable powers and duties, delegate some of its powers, in particular direct management, to a single
or to several of its members, managing directors, committees or to third parties who need be neither members of the board of directors
nor shareholders. Pursuant to Swiss law and Article 13 of our articles of association, details of the delegation and other procedural
rules such as quorum requirements must be set in the organizational rules issued by the board of directors.
Indemnification of Executive Management and
Directors
Subject to Swiss law, Article 17 of our
articles of association provides for indemnification of the existing and former members of the board of directors, executive management
and their heirs, executors and administrators, against liabilities arising in connection with the performance of their duties in
such capacity, and permits us to advance the expenses of defending any act, suit or proceeding to our directors and executive management.
In addition, under general principles of
Swiss employment law, an employer may be required to indemnify an employee against losses and expenses incurred by such employee
in the proper execution of their duties under the employment agreement with the employer.
We have entered into indemnification agreements
with each of the members of our board of directors and executive management. The indemnification agreements and our articles of
association require us to indemnify our directors and executive officers to the fullest extent permitted by law.
Conflict of Interest, Management Transactions
Swiss law does not provide for a general
provision regarding conflicts of interest. However, the CO contains a provision that requires our directors and executive management
to safeguard the Company’s interests and imposes a duty of loyalty and duty of care on our directors and executive management.
This rule is generally understood to disqualify directors and executive management from participation in decisions that directly
affect them. Our directors and executive officers are personally liable to us for breach of these provisions. In addition, Swiss
law contains provisions under which directors and all persons engaged in the Company’s management are liable to the Company,
each shareholder and the Company’s creditors for damages caused by an intentional or negligent violation of their duties.
Furthermore, Swiss law contains a provision under which payments made to any of the Company’s shareholders or directors or
any person associated with any such shareholder or director, other than payments made at arm’s length, must be repaid to
the Company if such shareholder or director acted in bad faith.
Our board of directors has adopted a Code
of Business Conduct and Ethics that covers a broad range of matters, including the handling of conflicts of interest.
Principles of the Compensation of the
Board of Directors and the Executive Management
Pursuant to Swiss law, our shareholders
must annually resolve on the approval of the compensation of the board of directors and the persons whom the board of directors
has, fully or partially, entrusted with the management of the Company. The board of directors must issue, on an annual basis, a
written compensation report that must be reviewed together with a report on our business by our auditor. The compensation report
must disclose all compensation, loans and other forms of indebtedness granted by the Company, directly or indirectly, to current
or former members of the board of directors and executive management to the extent related to their former role within the Company
or not on customary market terms.
The disclosure concerning compensation,
loans and other forms of indebtedness must include the aggregate amount for the board of directors and the executive management
as well as the particular amount for each member of the board of directors and executive officer, specifying the name and function
of each respective person.
Certain forms of compensation are prohibited
for members of our board of directors and executive management, such as:
|
·
|
severance payments provided for either contractually or in the articles of association (compensation due until the termination
of a contractual relationship does not qualify as severance payment);
|
|
·
|
incentive fees for the acquisition or transfer of corporations or parts thereof by the Company or by companies being, directly
or indirectly, controlled by us;
|
|
·
|
loans, other forms of indebtedness, pension benefits not based on occupational pension schemes and performance-based compensation
not provided for in the articles of association; and
|
|
·
|
equity securities and conversion and option rights awards not provided for in the articles of association.
|
Compensation to members of the board of
directors and executive management for activities in entities that are, directly or indirectly, controlled by the Company is prohibited
if the compensation (i) would have been prohibited if it was paid directly by the Company, (ii) is not provided for in the articles
of association or (iii) has not been approved by the general meeting of shareholders.
The general meeting of shareholders annually
votes on the proposals of the board of directors with respect to:
|
·
|
the maximum aggregate amount of compensation of the board of directors for the subsequent term of office; and
|
|
·
|
the maximum aggregate amount of compensation of the executive management for the subsequent financial year.
|
The board of directors may submit for approval
at the general meeting of shareholders deviating or additional proposals relating to the same or different periods.
In the event that at the general meeting
of shareholders the shareholders do not approve a proposal of the board of directors, the board of directors must form a new proposal
for the maximum aggregate compensation and the particular compensation for each individual, taking into account all relevant factors,
and submit the new proposal for approval by the same general meeting of shareholders, at a subsequent extraordinary general meeting
or the next ordinary general meeting of shareholders.
In addition to fixed compensation, members
of the board of directors and executive management may be paid variable compensation, depending on the achievement of certain performance
criteria. The performance criteria may include individual targets, targets of the Company or parts thereof and targets in relation
to the market, other companies or comparable benchmarks, taking into account the position and level of responsibility of the recipient
of the variable compensation. The board of directors or, where delegated to it, the compensation committee shall determine the
relative weight of the performance criteria and the respective target values.
Compensation may be paid or granted in
the form of cash, shares, financial instruments, in kind, or in the form of other types of benefits. The board of directors or,
where delegated to it, the compensation committee shall determine grant, vesting, exercise and forfeiture conditions.
Borrowing Powers
Neither Swiss law nor our articles of association
restrict in any way our power to borrow and raise funds. The decision to borrow funds is made by or under the direction of our
board of directors, and no approval by the shareholders is required in relation to any such borrowing.
Repurchases of Shares and Purchases of
Own Shares
The CO limits our right to purchase and
hold our own shares. We and our subsidiaries may purchase shares only if and to the extent that (i) we have freely distributable
reserves in the amount of the purchase price; and (ii) the aggregate nominal value of all shares held by us does not exceed 10
percent of our share capital. Pursuant to Swiss law, where shares are acquired in connection with a transfer restriction set out
in the articles of association, the foregoing upper limit is 20 percent. We currently do not have any transfer restriction in our
articles of association. If we own shares that exceed the threshold of 10 percent of our share capital, the excess must be sold
or cancelled by means of a capital reduction within two years.
Shares held by us or our subsidiaries are
not entitled to vote at the general meeting of shareholders but are entitled to the economic benefits applicable to the shares
generally, including dividends and pre-emptive rights in the case of share capital increases.
Notification and Disclosure of Substantial
Share Interests
The disclosure obligations generally applicable
to shareholders of Swiss corporations under the Swiss Financial Market Infrastructure Act do not apply to us since our shares are
not listed on a Swiss exchange.
Pursuant to art. 663c of the CO, Swiss
corporations whose shares are listed on a stock exchange must disclose their significant shareholders and their shareholdings in
the notes to their balance sheet, where this information is known or ought to be known. Significant shareholders are defined as
shareholders and groups of shareholders linked through voting rights who hold more than five percent of all voting rights.
Stock Exchange Listing
Our common shares are listed on the Nasdaq
Global Market under the symbol “EARS.”
The Depository Trust Company
Initial settlement of any common shares
to be issued pursuant to this prospectus will take place through The Depository Trust Company, or DTC, in accordance with its customary
settlement procedures for equity securities. Each person owning common shares held through DTC must rely on the procedures thereof
and on institutions that have accounts therewith to exercise any rights of a holder of the shares.
Transfer Agent and Registrar of Shares
Our share register is currently kept by
American Stock Transfer & Trust Company, LLC, which acts as transfer agent and registrar. The share register reflects only
record owners of our shares.
Related
Party Transactions
The Share Lender and the Share
Borrower have entered into a share lending agreement to facilitate the timely settlement of common shares sold under this
prospectus supplement due to certain Swiss legal requirements with respect to the issuance of common shares that could
otherwise delay settlement. Pursuant to the terms of the share lending agreement, the Share Lender will lend common shares to
the Share Borrower so that those common shares may be delivered by Cantor Fitzgerald & Co. to purchasers of common shares
sold under this prospectus supplement upon a “T+3” settlement schedule. The Share Borrower will return common
shares to the Share Lender upon the issuance of new common shares by us to the Share Borrower. Neither we nor the Share
Lender will receive any compensation for this arrangement.
Taxation
The following summary contains a description
of the material Swiss and U.S. federal income tax consequences of the acquisition, ownership and disposition of common shares,
but it does not purport to be a comprehensive description of all the tax considerations that may be relevant to a decision to purchase
common shares. The summary is based upon the tax laws of Switzerland and regulations thereunder and on the tax laws of the United
States and regulations thereunder as of the date hereof, which are subject to change.
Swiss Tax Considerations
This summary of material Swiss tax consequences
is based on Swiss law and regulations and the practice of the Swiss tax administration as in effect on the date hereof, all of
which are subject to change (or subject to changes in interpretation), possibly with retroactive effect. The summary does not purport
to take into account the specific circumstances of any particular shareholder or potential investor and does not relate to persons
in the business of buying and selling common shares or other securities. The summary is not intended to be, and should not be interpreted
as, legal or tax advice to any particular potential shareholder/s, and no representation with respect to the tax consequences to
any particular shareholder/s is made.
Current and prospective shareholders are
advised to consult their own tax advisers in light of their particular circumstances as to the Swiss tax laws, regulations and
regulatory practices that could be relevant for them in connection with the acquiring, owning and selling or otherwise disposing
of common shares and receiving dividends and similar cash or in-kind distributions on common shares (including dividends on liquidation
proceeds and stock dividends) or distributions on common shares based upon a capital reduction (
Nennwertrückzahlungen
)
or reserves paid out of capital contributions (
Reserven aus Kapitaleinlagen
) and the consequences thereof under the tax
laws, regulations and regulatory practices of Switzerland.
Taxation of Auris Medical Holding AG
Auris Medical Holding AG is a Swiss based
company, taxed as a holding company in the Canton of Zug. The company is taxed at a current effective income tax rate of 7.83%
(including direct federal as well as cantonal/communal taxes), whereby a participation relief applies to dividend income from qualifying
participations, and a current annual capital tax rate of 0.003% which is levied on the net equity of the company.
Switzerland is currently in the process
of reforming certain elements of its corporate tax law (Swiss Corporate Tax Reform III, “CTR III”). The current dispatch
of CTR III includes proposed changes which may impact the taxation of Auris Medical Holding AG (including the abolition of the
holding taxation at cantonal/communal level). If passed, the new rules are anticipated to enter into force around 2018 / 2019,
likely with a 2 year transition period for the cantons to adopt these new rules.
Swiss Federal Withholding Tax on Dividends and other
Distributions
Dividend payments and similar cash or in-kind
distributions on the common shares (including dividends on liquidation proceeds and stock dividends) that the Company makes to
shareholders are subject to Swiss federal withholding tax (
Verrechnungssteuer
) at a rate of 35% on the gross amount of the
dividend. The Company is required to withhold the Swiss federal withholding tax from the dividend and remit it to the Swiss Federal
Tax Administration. Distributions based upon a capital reduction (
Nennwertrückzahlungen
) and reserves paid out of capital
contributions (
Reserven aus Kapitaleinlagen
) are not subject to Swiss federal withholding tax.
The redemption of common shares in the
Company may under certain circumstances (in particular, if the common shares in the Company are redeemed for subsequent cancellation)
be taxed as a partial liquidation for Swiss federal withholding tax purposes, with the consequence that the difference between
the repurchase price and the nominal value of the shares (
Nennwertprinzip
) plus capital contribution reserves (
Reserven
aus Kapitaleinlagen
) is subject to Swiss federal withholding tax.
The Swiss federal withholding tax is refundable
or creditable in full to a Swiss tax resident corporate and individual shareholder as well as to a non-Swiss tax resident corporate
or individual shareholder who holds the
common shares as part of a trade or business
carried on in Switzerland through a permanent establishment or fixed place of business situated for tax purposes in Switzerland,
if such person is the beneficial owner of the distribution and, in the case of a Swiss tax resident individual who holds the common
shares as part of his private assets, duly reports the gross distribution received in his individual income tax return or, in the
case of a person who holds the common shares as part of a trade or business carried on in Switzerland through a permanent establishment
or fixed place of business situated for tax purposes in Switzerland, recognizes the gross dividend distribution for tax purposes
as earnings in the income statements and reports the annual profit in the Swiss income tax return.
If a shareholder who is not a Swiss resident
for tax purposes and does not hold the common shares in connection with the conduct of a trade or business in Switzerland through
a permanent establishment or fixed place of business situated, for tax purposes in Switzerland, receives a distribution from the
Company, the shareholder may be entitled to a full or partial refund or credit of Swiss federal withholding tax incurred on a taxable
distribution if the country in which such shareholder is resident for tax purposes has entered into a treaty for the avoidance
of double taxation with Switzerland and the further prerequisites of the treaty for a refund have been met. Shareholders not resident
in Switzerland should be aware that the procedures for claiming treaty benefits (and the time required for obtaining a refund or
credit) may differ from country to country.
Besides the bilateral treaties, Switzerland
has entered into an agreement with the European Community providing for measures equivalent to those laid down in Council Directive
2003/48/EC on taxation of savings income in the form of interest payments and the Council Directive 90/435/EWG on the taxation
of parent companies and subsidiaries of different Member States. This agreement contains in its Article 15 provisions on taxation
of dividends which apply with respect to EU member states and provides for an exemption of Withholding Tax for companies under
certain circumstances.
On January 1, 2013, treaties on final withholding
taxes entered into by Switzerland with the European Community and the individual European states came into force (each a “Contracting
State”). The treaties require a Swiss paying agent, as defined in the treaties, to levy a flat-rate final withholding tax
at rates specified in the treaties on certain capital gains and income items (including dividends), all as defined in the treaties,
deriving from assets, including the common shares held in account or deposits with a Swiss paying agent by (i) an individual resident
in a Contracting State, or (ii) if certain requirements are met, by a domiciliary company (
Sitzgesellschaft
), an insurance
company in connection with a so-called insurance wrapper (
Lebensversicherungsmantel
) or other individuals if the beneficial
owner is an individual resident in a Contracting State. Each contracting state has different tax rates on dividends and capital
gains for individuals resident and domiciled in one of the European states. The flat-rate tax withheld substitutes the ordinary
capital gains tax and income tax on the relevant capital gains and income items in the Contracting State where the individuals
are tax resident, unless the individuals elect for the flat-rate tax withheld to be treated as if it were a credit allowable against
the income tax or, as the case may be, capital gains tax, due for the relevant tax year in the relevant Contracting State. Alternatively,
instead of paying the flat-rate tax, such individuals may opt for a disclosure or the relevant capital gains and income items to
the tax authorities of the Contracting State where they are tax residents. If Swiss federal withholding tax of 35% has been withheld
on dividends, the Swiss paying agent will – to the extent provided in the applicable bilateral treaty for the avoidance of
double taxation between Switzerland and the Contracting State – in its own name and on behalf of the relevant shareholder
file with the Swiss tax authorities a request for the partial refund of the Swiss federal withholding tax. The Swiss federal withholding
tax which is not refundable according to the bilateral tax treaty (residual tax) is credited against the flat-rate final withholding
tax.
Individual and Corporate Income Tax on Dividends
Swiss resident individuals holding the
common shares as part of their private assets who receive dividends and similar distributions (including stock dividends and liquidation
proceeds), which are not repayments of the nominal value (
Nennwertrückzahlungen
) of the common shares or reserves paid
out of capital contributions (
Reserven aus Kapitaleinlagen
) are required to report such payments in their individual income
tax returns and are liable to Swiss federal, cantonal and communal income taxes on any net taxable income for the relevant tax
period. Furthermore, for the purpose of the Direct Federal Tax, dividends, shares in profits, liquidation proceeds and pecuniary
benefits from shares (including bonus shares) are included in the tax base for only 60% of their value (
Teilbesteuerung
),
if
the investment amounts to at least 10% of
nominal share capital of the Company. Most Swiss cantons have introduced similar partial taxation measures at cantonal and communal
levels.
Swiss resident individuals as well as non-Swiss
resident individual taxpayers holding the common shares in connection with the conduct of a trade or business in Switzerland through
a permanent establishment or fixed place of business situated, for tax purposes, in Switzerland, are required to recognize dividends,
distributions based upon a capital reduction (
Nennwertrückzahlungen
) and reserves paid out of capital contributions
(
Reserven aus Kapitaleinlagen
) in their income statements for the relevant tax period and are liable to Swiss federal, cantonal
and communal individual or corporate income taxes, as the case may be, on any net taxable earnings accumulated (including the payment
of dividends) for such period. Furthermore, for the purpose of the Direct Federal Tax, dividends, shares in profits, liquidation
proceeds and pecuniary benefits from shares (including bonus shares) are included in the tax base for only 50% (
Teilbesteuerung
),
if the investment is held in connection with the conduct of a trade or business or qualifies as an opted business asset (
gewillkürtes
Geschäftsvermögen
) according to Swiss tax law and amounts to at least 10% of nominal share capital of the Company.
All cantons have introduced similar partial taxation measures at cantonal and communal levels.
Swiss resident corporate taxpayers as well
as non-Swiss resident corporate taxpayers holding the common shares in connection with the conduct of a trade or business through
a permanent establishment or fixed place of business situated, for tax purposes, in Switzerland, are required to recognize dividends,
distributions based upon a capital reduction (
Nennwertrückzahlungen
) and reserves paid out of capital contributions
(
Reserven aus Kapitaleinlagen
) in their income statements for the relevant tax period and are liable to Swiss federal, cantonal
and communal corporate income taxes on any net taxable earnings accumulated for such period. Swiss resident corporate taxpayers
as well as non-Swiss resident corporate taxpayers holding the common shares in connection with the conduct of a trade or business
through a permanent establishment or fixed place of business situated, for tax purposes, in Switzerland may be eligible for participation
relief (
Beteiligungsabzug
) in respect of dividends and distributions based upon a capital reduction (
Nennwertrückzahlungen
)
and reserves paid out of capital contributions (
Reserven aus Kapitaleinlagen
) if the common shares held by them as part
of a Swiss business have an aggregate market value of at least CHF 1 million or represent at least 10% of the nominal share capital
of the Company or give entitlement to at least 10% of the profits and reserves of the Company, respectively.
Recipients of dividends and similar distributions
on the common shares (including stock dividends and liquidation proceeds) who neither are residents of Switzerland nor during the
current taxation year have engaged in a trade or business in Switzerland and who are not subject to taxation in Switzerland for
any other reason are not subject to Swiss federal, cantonal or communal individual or corporate income taxes in respect of dividend
payments and similar distributions because of the mere holding of the common shares.
Wealth and Annual Capital Tax on Holding of Common Shares
Swiss resident individuals and non-Swiss
resident individuals holding the common shares in connection with the conduct of a trade or business in Switzerland through a permanent
establishment or fixed place of business situated, for tax purposes, in Switzerland, are required to report their common shares
as part of their wealth and will be subject to cantonal and communal wealth tax to the extent the aggregate taxable net wealth
is allocable to Switzerland.
Swiss resident corporate taxpayers and
non-Swiss resident corporate taxpayers holding the common shares in connection with the conduct of a trade or business in Switzerland
through a permanent establishment or fixed place of business situated, for tax purposes, in Switzerland, will be subject to cantonal
and communal annual capital tax on the taxable capital to the extent the aggregate taxable capital is allocable to Switzerland.
Individuals and corporate taxpayers not
resident in Switzerland for tax purposes and not holding the common shares in connection with the conduct of a trade or business
in Switzerland through a permanent establishment or fixed place of business situated, for tax purposes, in Switzerland, are not
subject to wealth or annual capital tax in Switzerland because of the mere holding of the common shares.
Capital Gains on Disposal of Common Shares
Swiss resident individuals who sell or
otherwise dispose of the common shares realize a tax-free capital gain, or a non-deductible capital loss, as the case may be, provided
that they hold the common shares as part of their private assets. Under certain circumstances, the sale proceeds may be requalified
into taxable investment income (e.g., if the taxpayer is deemed to be a professional securities dealer).
Capital gains realized on the sale of the
common shares held by Swiss resident individuals, Swiss resident corporate taxpayers as well as non-Swiss resident individuals
and corporate taxpayers holding the common shares in connection with the conduct of a trade or business in Switzerland through
a permanent establishment or fixed place of business situated, for tax purposes, in Switzerland, will be subject to Swiss federal,
cantonal and communal individual or corporate income tax, as the case may be. This also applies to Swiss resident individuals who,
for individual income tax purposes, are deemed to be professional securities dealers for reasons of, inter alia, frequent dealing
and debt-financed purchases. Capital gains realized by resident individuals who hold the common shares as business assets might
be entitled to reductions or partial taxations similar to those mentioned above for dividends (
Teilbesteuerung
) if certain
conditions are met (e.g. holding period of at least one year and participation of at least 10% of nominal share capital).
Swiss resident corporate taxpayers as well
as non-Swiss resident corporate taxpayers holding the common shares in connection with the conduct of a trade or business, through
a permanent establishment or fixed place of business situated, for tax purposes, in Switzerland, are required to recognize such
capital gain in their income statements for the relevant tax period. Corporate taxpayers may qualify for participation relief on
capital gains (
Beteiligungsabzug
), if the common shares sold during the tax period represent at least 10% of the Company’s
share capital or if the common shares sold give entitlement to at least 10% of the Company’s profit and reserve and were
held for at least one year. The tax relief applies to the difference between the sale proceeds of common shares by the Company
and the acquisition costs of the participation (
Gestehungskosten
).
Individuals and corporations not resident
in Switzerland for tax purposes and not holding the common shares in connection with the conduct of a trade or business in Switzerland
through a permanent establishment or fixed place of business situated, for tax purposes, in Switzerland, are not subject to Swiss
federal, cantonal and communal individual income or corporate income tax, as the case may be, on capital gains realized on the
sale of the common shares.
Gift and Inheritance Tax
Transfers of common shares may be subject
to cantonal and/or communal inheritance or gift taxes if the deceased or the donor or the recipient were resident in a Canton levying
such taxes and, in international circumstances where residency requirements are satisfied, if the applicable tax treaty were to
allocate the right to tax to Switzerland.
Swiss Issuance Stamp Duty
The Company is subject to paying to the
Swiss Federal Tax Administration a 1% Swiss federal issuance stamp tax (
Emissionsabgabe
) on any increase of the nominal
share capital of the Company (with or without issuance of shares) or any other equity contributions received by the Company (regardless
of whether or not any compensation is paid to the shareholder in connection with the contribution). Certain costs incurred in connection
with the issuance of shares (if any) may be deductible. There are several exemptions from issuance stamp tax that may apply under
certain circumstances (e.g., certain intercompany reorganizations).
Swiss Securities Transfer Tax
The purchase or sale (or other financial
transfer) of the common shares, whether by Swiss residents or non-Swiss residents, may be subject to Swiss securities transfer
tax of up to 0.15%, calculated on the purchase price or the proceeds if the purchase or sale occurs through or with a Swiss bank
or other Swiss securities dealer as defined in the Swiss Federal Stamp Duty Act as an intermediary or party to the transaction
unless an exemption applies.
Material U.S. Federal Income Tax Considerations
for U.S. Holders
The following is a description of the material
U.S. federal income tax consequences to the U.S. Holders described below of owning and disposing of common shares, but it does
not purport to be a comprehensive description of all tax considerations that may be relevant to a particular person’s decision
to acquire the common shares. This discussion applies only to a U.S. Holder that holds common shares as capital assets for U.S.
federal income tax purposes. In addition, it does not describe all of the tax consequences that may be relevant in light of the
U.S. Holder’s particular circumstances, including alternative minimum tax consequences, the potential application of the
provisions of the Internal Revenue Code of 1986, as amended, or the Code, known as the Medicare contribution tax and tax consequences
applicable to U.S. Holders subject to special rules, such as:
|
·
|
certain financial institutions;
|
|
·
|
dealers or traders in securities who use a mark-to-market method of tax accounting;
|
|
·
|
persons holding common shares as part of a hedging transaction, straddle, wash sale, conversion transaction or integrated transaction
or persons entering into a constructive sale with respect to the common shares;
|
|
·
|
persons whose functional currency for U.S. federal income tax purposes is not the U.S. dollar;
|
|
·
|
entities classified as partnerships for U.S. federal income tax purposes;
|
|
·
|
tax-exempt entities, including an “individual retirement account” or “Roth IRA”;
|
|
·
|
persons that own or are deemed to own ten percent or more of our voting stock; or
|
|
·
|
persons holding shares in connection with a trade or business conducted outside of the United States.
|
If an entity that is classified as a partnership
for U.S. federal income tax purposes holds common shares, the U.S. federal income tax treatment of a partner will generally depend
on the status of the partner and the activities of the partnership. Partnerships holding common shares and partners in such partnerships
should consult their tax advisers as to their particular U.S. federal income tax consequences of holding and disposing of the common
shares.
This discussion is based on the Code, administrative
pronouncements, judicial decisions, final, temporary and proposed Treasury regulations, and the income tax treaty between Switzerland
and the United States, or the Treaty, all as of the date hereof, any of which is subject to change, possibly with retroactive effect.
A “U.S. Holder” is a holder
who, for U.S. federal income tax purposes, is a beneficial owner of common shares who is eligible for the benefits of the Treaty
and is:
|
·
|
an individual who is a citizen or resident of the United States;
|
|
·
|
a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any
state therein or the District of Columbia; or
|
|
·
|
an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source.
|
U.S. Holders should consult their tax advisers
concerning the U.S. federal, state, local and non-U.S. tax consequences of owning and disposing of common shares in their particular
circumstances.
Passive Foreign Investment Company Rules
We believe that we were a “passive
foreign investment company,” or PFIC, for U.S. federal income tax purposes for our 2014 and 2015 taxable years, and we expect
to be a PFIC for our current taxable year and for the foreseeable future. In addition, we may, directly or indirectly, hold equity
interests in other PFICs, or Lower-tier PFICs. In general, a non-U.S. corporation will be considered a PFIC for any taxable year
in which (i) 75% or more
of its gross income consists of passive income
or (ii) 50% or more of the average quarterly value of its assets consists of assets that produce, or are held for the production
of, passive income. For purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25%
by value of the shares of another corporation is treated as if it held its proportionate share of the assets of the other corporation
and received directly its proportionate share of the income of the other corporation. Passive income generally includes dividends,
interest, rents, royalties and capital gains.
Under attribution rules, if we are a PFIC,
U.S. Holders will be deemed to own their proportionate shares of Lower-tier PFICs and will be subject to U.S. federal income tax
according to the rules described in the following paragraphs on (i) certain distributions by a Lower-tier PFIC and (ii) a disposition
of shares of a Lower-tier PFIC, in each case as if the U.S. Holder held such shares directly, even though holders have not received
the proceeds of those distributions or dispositions directly.
If we are a PFIC for any taxable year during
which a U.S. Holder holds our shares, the U.S. Holder may be subject to certain adverse tax consequences. Unless a holder makes
a timely “mark-to-market” election or “qualified electing fund” election, each as discussed below, gain
recognized on a disposition (including, under certain circumstances, a pledge) of common shares by the U.S. Holder, or on an indirect
disposition of shares of a Lower-tier PFIC, will be allocated ratably over the U.S. Holder’s holding period for the shares.
The amounts allocated to the taxable year of disposition and to years before we became a PFIC will be taxed as ordinary income.
The amounts allocated to each other taxable year will be subject to tax at the highest rate in effect for that taxable year for
individuals or corporations, as appropriate, and an interest charge will be imposed on the tax attributable to the allocated amounts.
Further, to the extent that any distribution received by a U.S. Holder on our common shares (or a distribution by a Lower-tier
PFIC to its shareholder that is deemed to be received by a U.S. Holder) exceeds 125% of the average of the annual distributions
on the shares received during the preceding three years or the U.S. Holder’s holding period, whichever is shorter, the distribution
will be subject to taxation in the same manner as gain, described immediately above.
If we are a PFIC for any year during which
a U.S. Holder holds common shares, we generally will continue to be treated as a PFIC with respect to the holder for all succeeding
years during which the U.S. Holder holds common shares, even if we cease to meet the threshold requirements for PFIC status. U.S.
Holders should consult their tax advisers regarding the potential availability of a “deemed sale” election that would
allow them to eliminate this continuing PFIC status under certain circumstances.
If the common shares are “regularly
traded” on a “qualified exchange,” a U.S. Holder may make a mark-to-market election that would result in tax
treatment different from the general tax treatment for PFICs described above. The common shares will be treated as “regularly
traded” in any calendar year in which more than a
de minimis
quantity of the common shares is traded on a qualified
exchange on at least 15 days during each calendar quarter. Nasdaq, on which the common shares are listed, is a qualified exchange
for this purpose. U.S. Holders should consult their tax advisers regarding the availability and advisability of making a mark-to-market
election in their particular circumstances. In particular, U.S. Holders should consider carefully the impact of a mark-to-market
election with respect to their common shares given that we may have Lower-tier PFICs for which a mark-to-market election may not
be available.
If a U.S. Holder makes the mark-to-market
election, the holder generally will recognize as ordinary income any excess of the fair market value of the common shares at the
end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted
tax basis of the common shares over their fair market value at the end of the taxable year (but only to the extent of the net amount
of income previously included as a result of the mark-to-market election). If a U.S. Holder makes the election, the holder’s
tax basis in the common shares will be adjusted to reflect the income or loss amounts recognized. Any gain recognized on the sale
or other disposition of common shares in a year when we are a PFIC will be treated as ordinary income and any loss will be treated
as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the mark-to-market election).
Distributions paid on common shares will be treated as discussed below under “
Taxation of Distributions
.”
Alternatively, a U.S. Holder can make an
election, if we provide the necessary information, to treat us and each Lower-tier PFIC as a qualified electing fund (a “QEF
Election”) in the first taxable year that we are treated as a PFIC with respect to the holder. A U.S. Holder must make the
QEF Election for each PFIC by attaching a separate properly completed IRS Form 8621 for each PFIC to the holder’s timely
filed U.S. federal income tax return. Upon request of a U.S. Holder, we will provide the information necessary for a U.S. Holder
to make a QEF Election with respect to us and will use commercially reasonable efforts to cause each Lower-tier PFIC which we control
to provide such information with respect to such Lower-tier PFIC. However, no assurance can be given that such QEF information
will be available for any Lower-tier PFIC.
If a U.S. Holder makes a QEF Election with
respect to a PFIC, the holder will be currently taxable on its
pro rata
share of the PFIC’s ordinary earnings and
net capital gain (at ordinary income and capital gain rates, respectively) for each taxable year that the entity is classified
as a PFIC. If a U.S. Holder makes a QEF Election with respect to us, any distributions paid by us out of our earnings and profits
that were previously included in the holder’s income under the QEF Election would not be taxable to the holder. A U.S. Holder
will increase its tax basis in its common shares by an amount equal to any income included under the QEF Election and will decrease
its tax basis by any amount distributed on the common shares that is not included in the holder’s income. In addition, a
U.S. Holder will recognize capital gain or loss on the disposition of common shares in an amount equal to the difference between
the amount realized and the holder’s adjusted tax basis in the common shares. U.S. Holders should note that if they make
QEF Elections with respect to us and Lower-tier PFICs, they may be required to pay U.S. federal income tax with respect to their
common shares for any taxable year significantly in excess of any cash distributions received on the shares for such taxable year.
U.S. Holders should consult their tax advisers regarding making QEF Elections in their particular circumstances.
Furthermore, if we were a PFIC or, with
respect to a particular U.S. Holder, were treated as a PFIC for the taxable year in which we paid a dividend or the prior taxable
year, the preferential dividend rate with respect to dividends paid to certain non-corporate U.S. Holders would not apply.
If we were a PFIC for any taxable year
during which a U.S. Holder held common shares, such U.S. Holder would be required to file an annual information report with such
U.S. Holder’s U.S. Federal income tax return on IRS Form 8621.
U.S. Holders should consult their tax advisers
concerning our PFIC status and the tax considerations relevant to an investment in a PFIC.
Taxation of Distributions
As discussed above under “Dividend
Policy,” we do not currently expect to make distributions on our common shares. In the event that we do make distributions
of cash or other property, subject to the passive foreign investment company rules described above, distributions paid on common
shares, other than certain
pro rata
distributions of common shares, will be treated as dividends to the extent paid out
of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). The amount of a dividend
will include any amounts withheld by us in respect of Swiss taxes. The amount of the dividend will be treated as foreign-source
dividend income to U.S. Holders and will not be eligible for the dividends-received deduction generally available to U.S. corporations
under the Code. Dividends will be included in a U.S. Holder’s income on the date of the U.S. Holder’s receipt of the
dividend. The amount of any dividend income paid in Swiss Francs will be the U.S. dollar amount calculated by reference to the
exchange rate in effect on the date of receipt, regardless of whether the payment is in fact converted into U.S. dollars. If the
dividend is converted into U.S. dollars on the date of receipt, a U.S. Holder should not be required to recognize foreign currency
gain or loss in respect of the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted
into U.S. dollars after the date of receipt.
Subject to applicable limitations, some
of which vary depending upon the U.S. Holder’s circumstances, Swiss income taxes withheld from dividends on common shares
at a rate not exceeding the rate provided by the Treaty may be creditable against the U.S. Holder’s U.S. federal income tax
liability. Swiss taxes withheld in excess of the rate applicable under the Treaty will not be eligible for credit against a U.S.
Holder’s federal income tax liability. The rules governing foreign tax credits are complex, and U.S. Holders should consult
their tax advisers regarding
the creditability of foreign taxes in their
particular circumstances. In lieu of claiming a foreign tax credit, U.S. Holders may, at their election, deduct foreign taxes,
including the Swiss tax, in computing their taxable income, subject to generally applicable limitations under U.S. law. An election
to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year.
Sale or Other Disposition of Common Shares
Subject to the passive foreign investment
company rules described above, for U.S. federal income tax purposes, gain or loss realized on the sale or other disposition of
common shares will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder held the common shares
for more than one year. The amount of the gain or loss will equal the difference between the U.S. Holder’s tax basis in the
common shares disposed of and the amount realized on the disposition, in each case as determined in U.S. dollars. This gain or
loss will generally be U.S.-source gain or loss for foreign tax credit purposes.
Information Reporting and Backup Withholding
Payments of dividends and sales proceeds
that are made within the United States or through certain U.S.-related financial intermediaries generally are subject to information
reporting, and may be subject to backup withholding, unless (i) the U.S. Holder is a corporation or other exempt recipient or (ii)
in the case of backup withholding, the U.S. Holder provides a correct taxpayer identification number and certifies that it is not
subject to backup withholding.
The amount of any backup withholding from
a payment to a U.S. Holder will be allowed as a credit against the holder’s U.S. federal income tax liability and may entitle
it to a refund, provided that the required information is timely furnished to the IRS.
Information With Respect to Foreign Financial
Assets
Certain U.S. Holders who are individuals
and certain entities may be required to report information relating to an interest in our common shares, subject to certain exceptions
(including an exception for common shares held in accounts maintained by certain U.S. financial institutions). U.S. Holders should
consult their tax advisers regarding the effect, if any, of this legislation on their ownership and disposition of the common shares.
FATCA
Provisions of the Code and Treasury regulations
thereunder commonly referred to as “FATCA” may impose 30% withholding on certain payments that are considered “foreign
passthru payments” made by a non-U.S. financial institution (such as the Company or a relevant intermediary) that has entered
into an agreement with the IRS to perform certain diligence and reporting obligations with respect to the financial institution’s
U.S.-owned accounts (each such non-U.S. financial institution, a “Participating Foreign Financial Institution”). If
the Company (or any relevant intermediary) becomes a Participating Foreign Financial Institution, this withholding tax may be imposed
on payments on common shares to any non-U.S. financial institution (including an intermediary through which a holder may hold common
shares) that is not a Participating Foreign Financial Institution and is not otherwise exempt from FATCA and to other holders who
do not provide sufficient identifying information, to the extent such payments are considered “foreign passthru payments.”
Under current guidance, the term “foreign passthru payment” is not defined and therefore it is not clear whether or
to what extent payments on the common shares would be considered foreign passthru payments subject to FATCA withholding. Withholding
on foreign passthru payments would not be required with respect to payments made before January 1, 2019.
The United States has entered into intergovernmental
agreements (“IGAs”) with certain jurisdictions, including Switzerland, that may modify the FATCA withholding regime
described above. It is not yet clear how these IGAs will address “foreign passthru payments” and whether such agreements
may relieve a financial institution, that is subject to an IGA, of any obligation to withhold on foreign passthru payments.
FATCA is particularly complex and holders
of common shares should consult their tax advisers regarding the implications of FATCA, any relevant IGA and any non-U.S. legislation
implementing FATCA or an IGA on their investment in common shares.
Plan of
Distribution
We have entered into a Controlled Equity
Offering
SM
sales agreement with Cantor Fitzgerald & Co. under which we may issue and sell from time to time up to
$35,000,000 of our common shares through Cantor Fitzgerald & Co. as our sales agent. The sales agreement has been filed as
an exhibit to a Report on Form 6-K and is incorporated by reference into this prospectus supplement. Sales of our common shares,
if any, will be made by means of ordinary brokers’ transactions on the NASDAQ Global Market at market prices. As our sales
agent, Cantor Fitzgerald & Co. will not engage in any transactions that stabilize our common shares.
Upon delivery of a placement notice
and subject to the terms and conditions of the sales agreement, Cantor Fitzgerald & Co. may sell our common shares by any
method permitted by law deemed to be an “at the market offering” as defined in Rule 415 promulgated under the
Securities Act, including sales made directly on the NASDAQ Global Market, on any other existing trading market for our
common shares or to or through a market maker. Cantor may also sell our common shares by any other method permitted by law,
including in negotiated transactions with our prior written consent. We will designate the maximum amount of our common
shares to be sold through Cantor Fitzgerald & Co. on a daily basis or otherwise determine such maximum amount together
with Cantor Fitzgerald & Co. Subject to the terms and conditions of the sales agreement, Cantor Fitzgerald & Co. will
use its commercially reasonable efforts as the sales agent, consistent with its sales and trading practices, to sell on our
behalf all of the designated common shares. We may instruct Cantor Fitzgerald & Co. not to sell our common shares if the
sales cannot be effected at or above the price designated by us in any such instruction. We or Cantor Fitzgerald & Co.
may suspend the offering of our common shares under the sales agreement upon notice and subject to other conditions.
Cantor Fitzgerald & Co. will receive
from us a commission equal to 3.25% of the gross sales price per share for any common shares sold through it as our sales agent
under the sales agreement. The remaining sales proceeds, after deducting any expenses payable by us and any transaction fees imposed
by any governmental, regulatory or self-regulatory organization in connection with the sales, will equal our net proceeds for the
sale of such common shares. Because there is no minimum offering amount required as a condition to close this offering, the actual
total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We have also agreed to
reimburse Cantor Fitzgerald & Co. for certain specified expenses, including the fees and disbursements of its legal counsel
in an amount not to exceed $200,000. We estimate that the total expenses of the offering payable by us, excluding discounts, commissions
and reimbursements payable to Cantor Fitzgerald & Co. under the sales agreement, will be approximately $255,000.
Settlement for sales of our common shares
will occur, unless the parties agree otherwise, on the third business day following the date on which any sales were made in return
for payment of the net proceeds to us. Sales of our common shares as contemplated in this prospectus will be settled through the
facilities of The Depository Trust Company or by such other means as we and Cantor Fitzgerald & Co. may agree upon.
The Share Lender and the Share
Borrower have entered into a share lending agreement to facilitate the timely settlement of common shares sold under this
prospectus supplement due to certain Swiss legal requirements with respect to the issuance of common shares that could
otherwise delay settlement. Pursuant to the terms of the share lending agreement, the Share Lender will lend common shares to
the Share Borrower so that those common shares may be delivered by Cantor Fitzgerald & Co. to purchasers of common shares
sold under this prospectus supplement upon a “T+3” settlement schedule. The Share Borrower will return common
shares to the Share Lender upon the issuance of new common shares by us to the Share Borrower. Neither we nor the Share
Lender will receive any compensation for this arrangement.
In connection with the sale of our common
shares on our behalf, Cantor Fitzgerald & Co. will be deemed to be an “underwriter” within the meaning of the Securities
Act, and the compensation paid to Cantor Fitzgerald & Co. will be deemed to be underwriting commissions or discounts. We have
agreed in the sales agreement to provide indemnification and contribution to Cantor Fitzgerald & Co. against certain civil
liabilities, including liabilities under the Securities Act.
Cantor Fitzgerald & Co. and its affiliates
may in the future provide investment banking, commercial banking and other financial services for us in the ordinary course of
business, for which services that may in the future receive customary fees. To the extent required by Regulation M, Cantor Fitzgerald
will not engage in any market making activities involving our common shares while the offering is ongoing under this prospectus
supplement.
The offering of our common shares pursuant
to the sales agreement will terminate upon the termination of the sales agreement as permitted therein. We and Cantor Fitzgerald
& Co. may each terminate the sales agreement at any time upon 10 days’ prior notice.
This prospectus supplement in electronic
format may be made available on a website maintained by Cantor Fitzgerald & Co., and Cantor Fitzgerald & Co. may distribute
this prospectus supplement and the accompanying base prospectus electronically.
Legal Matters
The validity of the common shares and certain
other matters of Swiss law will be passed upon for us by Walder Wyss Ltd., Zurich, Switzerland. Certain matters of U.S. federal
and New York State law will be passed upon for us by Davis Polk & Wardwell LLP, New York, New York. Cantor Fitzgerald &
Co. is being represented in connection with this offering by Cooley LLP, New York, New York, and, with respect to Swiss law, Homburger
AG, Zurich, Switzerland.
Experts
The consolidated financial statements of
Auris Medical Holding AG as of December 31, 2015 and 2014, and for each of the two years in the period ended December 31, 2015,
incorporated by reference in this prospectus supplement from Auris Medical Holding AG’s Annual Report on Form 20-F for the
year ended December 31, 2015, have been audited by Deloitte AG, an independent registered public accounting firm, as stated in
their report, which is incorporated by reference herein. Such consolidated financial statements have been so incorporated in reliance
upon the report of such firm, given upon their authority as experts in accounting and auditing.
The current address of Deloitte AG
is General Guisan-Quai 38, 8002 Zurich, Switzerland, phone number +(41) 58 279 60 00.
The consolidated financial statements of
Auris Medical Holding AG (formerly Auris Medical AG) as of December 31, 2013 and for the year ended December 31, 2013, have been
incorporated by reference herein in reliance upon the report of KPMG AG, independent registered public accounting firm, incorporated
by reference herein, and upon the authority of said firm as experts in accounting and auditing.
The current address of KPMG AG is
Badenerstrasse 172, 8004 Zurich, Switzerland.
Where You
Can Find More Information and Incorporation by Reference
We are subject to the informational requirements
of the Exchange Act. Accordingly, we are required to file reports and other information with the SEC, including annual reports
on Form 20-F and reports on Form 6-K. You may inspect and copy reports and other information filed with the SEC at the Public Reference
Room at 100 F Street, N.E., Washington, D.C. 20549. Information on the operation of the Public Reference Room may be obtained by
calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an Internet website that contains reports and other information
about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov.
The SEC allows us to incorporate by reference
information into this prospectus supplement. This means that we can disclose important information to you by referring you to another
document filed separately with the SEC. The information incorporated by reference is considered to be a part of this document,
except for any information superseded by information that is included directly in this prospectus supplement or incorporated by
reference subsequent to the date of this prospectus supplement.
We incorporate by reference the following
documents or information that we have filed with the SEC
|
·
|
our Annual Report on Form 20-F for the fiscal year ended December 31, 2015;
|
|
·
|
our Reports on Form 6-K filed on April 11, 2016, May 11, 2016 (other than Exhibit 99.3 thereto) and June 1, 2016; and
|
|
·
|
The description of our common shares contained in our registration statement on Form 8-A filed with the SEC on July 29, 2014,
including any amendments or reports filed for the purpose of updating such description.
|
All annual reports we file with the SEC
pursuant to the Exchange Act on Form 20-F after the date of this prospectus supplement and prior to termination of the offering
under this prospectus supplement shall be deemed incorporated by reference into this prospectus supplement and to be part hereof
from the date of filing of such documents. We may incorporate by reference any Form 6-K subsequently submitted to the SEC by identifying
in such Form 6-K that it is being incorporated by reference into this prospectus supplement.
Documents incorporated by reference in
this prospectus are available from us without charge upon written or oral request, excluding any exhibits to those documents that
are not specifically incorporated by reference into those documents. You can obtain documents incorporated by reference in this
document by requesting them from us in writing or at Auris Medical Holding AG, Bahnhofstrasse 21, 6300 Zug, Switzerland or via
telephone at +41 (0)41 729 71 94.
PROSPECTUS
$100,000,000
Common Shares, Debt Securities, Warrants, Purchase Contracts
and Units offered by the Company
Auris Medical
Holding AG
(incorporated in Switzerland)
We may offer, from time to time, in one
or more offerings, common shares, senior debt securities, subordinated debt securities, warrants, purchase contracts or units,
which we collectively refer to as the “securities.” The aggregate initial offering price of the securities that we
may offer and sell under this prospectus will not exceed $100,000,000. We may offer and sell any combination of the securities
described in this prospectus in different series, at times, in amounts, at prices and on terms to be determined at or prior to
the time of each offering. This prospectus describes the general terms of these securities and the general manner in which these
securities will be offered. We will provide the specific terms of these securities in supplements to this prospectus. The prospectus
supplements will also describe the specific manner in which these securities will be offered and may also supplement, update or
amend information contained in this prospectus. You should read this prospectus and any applicable prospectus supplement before
you invest.
The securities covered by this prospectus
may be offered through one or more underwriters, dealers and agents, or directly to purchasers. The names of any underwriters,
dealers or agents, if any, will be included in a supplement to this prospectus. For general information about the distribution
of securities offered, please see “Plan of Distribution” beginning on page 25.
Our common shares are listed on the
Nasdaq Global Market under the symbol “EARS.” On August 31, 2015, the last sale price of our common shares as
reported by the Nasdaq Global Market was $4.76 per common share. As of August 31, 2015, the aggregate market value of
our outstanding common shares held by non-affiliates was approximately $76.7 million based on approximately 34,293,891
outstanding common shares, of which approximately 16,122,393 common shares were held by non-affiliates. We have not offered
any securities pursuant to General Instruction I.B.5 of Form F-3 during the prior 12 calendar month period that ends on, and
includes, the date of this prospectus.
Investing in our securities involves
risks. See “Risk Factors” beginning on page 3 of this prospectus.
Neither the U.S. Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus is
September 10, 2015.
You should rely only on the information
contained in or incorporated by reference in this prospectus or any related prospectus supplement we provide to you. We have not
authorized anyone to provide you with different or additional information. We are not making an offer of securities in any state
where the offer is not permitted. You should not assume that the information contained in or incorporated by reference in this
prospectus is accurate as of any date other than the date on the front of this prospectus. Unless otherwise noted or the context
otherwise requires, references in this prospectus to “Auris Medical,” “the Company,” “our company,”
“we,” “us” or “our” refer to Auris Medical Holding AG (Auris Medical AG prior to our corporate
reorganization on April 22, 2014) and its subsidiaries.
table
of contents
Page
About This
Prospectus
This prospectus is part of a registration
statement that we filed with the Securities and Exchange Commission, or the SEC, utilizing a “shelf” registration process.
Under this shelf process, we may sell any combination of the securities described in this prospectus in one or more offerings.
This prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide
a prospectus supplement that will contain specific information about the terms of that offering. The prospectus supplement may
also add, update or change information contained in this prospectus. You should read both this prospectus and any prospectus supplement
together with additional information described under the headings “Where You Can Find More Information” and “Incorporation
of Certain Information by Reference.”
We have filed or incorporated by reference
exhibits to the registration statement of which this prospectus forms a part. You should read the exhibits carefully for provisions
that may be important to you.
Neither the delivery of this prospectus
nor any sale made under it implies that there has been no change in our affairs or that the information in this prospectus is correct
as of any date after the date of this prospectus. You should not assume that the information in this prospectus, including any
information incorporated in this prospectus by reference, the accompanying prospectus supplement or any free writing prospectus
prepared by us, is accurate as of any date other than the date on the front of those documents. Our business, financial condition,
results of operations and prospects may have changed since that date.
You should not assume that the information
contained in this prospectus is accurate as of any other date.
Where You
Can Find More Information
We file annual reports on Form 20-F, reports
on Form 6-K, and other information with the SEC under the Securities Exchange Act of 1934, as amended, or the Exchange Act. You
may read and copy this information at the following location of the SEC: Public Reference Room, 100 F Street, N.E., Washington,
D.C. 20549.
You may obtain information on the operation
of the SEC’s Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains an Internet site that contains
reports and other information about issuers like us who file electronically with the SEC. The address of the site is
http:
/
/www.sec.gov
.
As a foreign private issuer, we are exempt
under the Exchange Act from, among other things, the rules prescribing the furnishing and content of proxy statements, and our
directors, executive officers and principal shareholders are exempt from the reporting and short-swing profit recovery provisions
contained in Section 16 of the Exchange Act.
Special
Note Regarding Forward-Looking Statements
This prospectus and the financial statements
and other documents incorporated by reference in this prospectus contain forward-looking statements, including statements concerning
our industry, our operations, our anticipated financial performance and financial condition, and our business plans and growth
strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Exchange Act. The words “may,”
“might,” “will,” “should,” “estimate,” “project,” “plan,”
“anticipate,” “expect,” “intend,” “outlook,” “believe” and other similar
expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our
management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.
The following represent some, but not necessarily
all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our
forward-looking statements:
|
·
|
our operation as a development stage company with limited operating history and a history of operating losses;
|
|
·
|
our need for substantial additional funding before we can expect to become profitable from sales of our products;
|
|
·
|
our dependence on the success of AM-101 and AM-111, which are still in clinical development and may eventually prove to be
unsuccessful;
|
|
·
|
the chance that we may become exposed to costly and damaging liability claims resulting from the testing of our product candidates
in the clinic or in the commercial stage;
|
|
·
|
uncertainty surrounding whether and when any of our product candidates will receive regulatory approval, which is necessary
before they can be commercialized;
|
|
·
|
if our product candidates obtain regulatory approval, our being subject to expensive ongoing obligations and continued regulatory
overview;
|
|
·
|
enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval and commercialization;
|
|
·
|
the chance that we do not obtain orphan drug exclusivity for AM-111, which would allow our competitors to sell products that
treat the same conditions;
|
|
·
|
dependence on governmental authorities and health insurers establishing adequate reimbursement levels and pricing policies;
|
|
·
|
our products may not gain market acceptance, in which case we may not be able to generate product revenues;
|
|
·
|
our reliance on our current strategic relationships with INSERM or Xigen and the potential failure to enter into new strategic
relationships;
|
|
·
|
our reliance on third parties to conduct our nonclinical and clinical trials and on third-party single-source suppliers to
supply or produce our product candidates; and
|
|
·
|
other risk factors set forth in our most recent Annual Report on Form 20-F.
|
Our actual results or performance could
differ materially from those expressed in, or implied by, any forward-looking statements relating to those matters. Accordingly,
no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if
any of them do so, what impact they will have on our results of operations, cash flows or financial condition. Except as required
by law, we are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking
statement, whether written or oral, that may be made from time to time, whether as a result of new information, future events or
otherwise.
Auris Medical
Holding AG
We are a clinical-stage biopharmaceutical
company focused on the development of novel products for the treatment of inner ear disorders. Our most advanced product candidate,
AM-101, is in Phase 3 clinical development for acute inner ear tinnitus under a special protocol assessment, or SPA, from the Food
and Drug Administration, or the FDA. In two recently completed Phase 2 clinical trials, AM-101 demonstrated a favorable safety
profile and statistically significant improvement in tinnitus loudness and other patient reported outcomes. We are also developing
AM-111 for acute inner ear hearing loss. We are preparing two pivotal clinical trials in the treatment of idiopathic sudden sensorineural
hearing loss, or ISSNHL, titled Efficacy and Safety of AM-111 in the treatment of Acute Inner Ear Hearing Loss, or HEALOS, and
Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment, or ASSENT. In addition, we are preparing a
Phase 2 trial titled Efficacy and Safety of AM-111 in the Treatment of Surgery Induced Hearing Loss following Cochlear Implantation,
or REACH. Both acute
inner ear tinnitus and hearing loss are conditions
for which there is high unmet medical need, and we believe that we have the potential to be the first to market in these indications.
On April 22, 2014, we changed our name
from Auris Medical AG to Auris Medical Holding AG and transferred our operational business to our newly incorporated subsidiary
Auris Medical AG, which is now our main operating subsidiary. The common shares covered by this prospectus refer to the common
shares of Auris Medical Holding AG. The offices of Auris Medical Holding AG are located at Bahnhofstrasse 21, 6300 Zug, Switzerland.
Our telephone number is +41 (0) 41 729 71 94. Investors should contact us for any inquiries at the address and telephone number
of our principal executive office. Our principal website is
www.aurismedical.com
. The information contained on our website
is not a part of this prospectus.
Risk Factors
Before making a decision to invest in our
securities, you should carefully consider the risks described under “Risk Factors” in the applicable prospectus supplement
and in our then most recent Annual Report on Form 20-F, and in any updates to those risk factors in our reports on Form 6-K incorporated
herein, together with all of the other information appearing or incorporated by reference in this prospectus and any applicable
prospectus supplement, in light of your particular investment objectives and financial circumstances.
Ratio of
Earnings to Fixed Charges
The following table sets forth our ratio
of earnings to fixed charges for each of the periods indicated. You should read this table in conjunction with the consolidated
financial statements and notes incorporated by reference in this prospectus.
|
Six
Months
Ended June 30, 2015
|
Fiscal
Year Ended December 31,
|
|
2014
|
2013
|
2012
|
|
(Unaudited)
|
|
|
|
Ratio of earnings to fixed charges
|
*
|
*
|
*
|
*
|
|
*
|
Our earnings were insufficient to cover fixed charges by CHF 53,000 for the six months ended June 30, 2015 and CHF 95,000,
CHF 80,915 and CHF 38,000 for the years ended December 31, 2014, 2013 and 2012, respectively.
|
For purposes of calculating the ratios in
the table above, earnings consist of net profit/(loss) before income taxes plus fixed charges. Fixed charges consist of rental
expenses and cash relevant interest expenses.
Use of Proceeds
Unless otherwise indicated in a prospectus
supplement, the net proceeds from our sale of the securities will be used for general corporate purposes and other business opportunities.
Description
of Share Capital and Articles of Association
The Company
We are
a Swiss stock corporation (
Aktiengesellschaft
) organized under the laws of Switzerland. We were formed in 1998. We are currently
registered in Zug, Switzerland. Our head office is currently located at Bahnhofstrasse 21, 6300 Zug, Switzerland.
Share Capital
As of the date of this prospectus, our
issued fully paid-in share capital consists of CHF 13,717,556.40, divided into common shares with a nominal value of CHF 0.40 each
and no preferred shares.
Articles of Association
When
we refer to our articles of association in this prospectus, we refer to our amended and restated articles of association dated
as of May 18, 2015.
Ordinary Capital Increase, Authorized
and Conditional Share Capital
Under Swiss law, we may increase our share
capital (
Aktienkapital
) with a resolution of the general meeting of shareholders (ordinary capital increase) that must be
carried out by the board of directors within three months in order to become effective. In the case of subscription and increase
against payment of contributions in cash, a resolution passed by an absolute majority of the shares represented at the general
meeting of shareholders is required. In the case of subscription and increase against contributions in kind or to fund acquisitions
in kind, when shareholders’ statutory pre-emptive rights are withdrawn or where transformation of reserves into share capital
is involved, a resolution passed by two-thirds of the shares represented at a general meeting of shareholders and the absolute
majority of the nominal amount of the shares represented is required.
Our shareholders, by a resolution passed
by two-thirds of the shares represented at a general meeting of shareholders and the absolute majority of the nominal amount of
the shares represented, may empower our board of directors to issue shares of a specific aggregate nominal amount up to a maximum
of 50% of the share capital in the form of:
|
·
|
conditional capital (
bedingtes Kapital
) for the purpose of issuing shares in connection with, among other things, (i)
option and conversion rights granted in connection with warrants and convertible bonds issued by the Company or one of our subsidiaries
or (ii) grants of rights to employees, members of our board of directors or consultants or our subsidiaries to subscribe for new
shares (conversion or option rights); and/or
|
|
·
|
authorized capital (
genehmigtes Kapital
) to be utilized by the board of directors within a period determined by the
shareholders but not exceeding two years from the date of the shareholder approval.
|
Pre-emptive Rights
Pursuant to the Swiss Code of Obligations,
or CO, shareholders have pre-emptive rights (
Bezugsrechte
) to subscribe for new issuances of shares. With respect to conditional
capital in connection with the issuance of conversion rights, convertible bonds or similar debt instruments, shareholders have
advance subscription rights (
Vorwegzeichnungsrechte
) for the subscription of conversion rights, convertible bonds or similar
debt instruments.
A resolution passed at a general meeting
of shareholders by two-thirds of the shares represented and the absolute majority of the nominal value of the shares represented
may authorize our board of directors to withdraw or limit pre-emptive rights and/or advance subscription rights in certain circumstances.
If pre-emptive rights are granted, but
not exercised, the board of directors may allocate the pre-emptive rights as it elects.
With respect to our authorized share capital,
the board of directors is authorized by our articles of association to withdraw or to limit the pre-emptive rights of shareholders,
and to allocate them to third parties or to us, in the event that the newly issued shares are used for the purpose of:
|
·
|
expanding the shareholder base in certain capital markets or in the context of the listing, admission to official trading or
registration of the shares at domestic or international stock exchanges;
|
|
·
|
granting an over-allotment option to underwriters in connection with a placement of shares;
|
|
·
|
share placements, provided the issue price is determined by reference to the market price;
|
|
·
|
the participation of our employees, members of the board of directors or consultants or of one of our subsidiaries in one or
several equity incentive plans created by the board of directors;
|
|
·
|
the acquisition of companies, assets, participations or new investment projects or for public or private share placements for
the financing and/or refinancing of such transactions;
|
|
·
|
for raising equity capital in a fast and flexible manner as such transaction would be difficult to carry out without the withdrawal
of the pre-emptive rights of the existing shareholders; or
|
|
·
|
the acquisition of a participation in us by a strategic partner.
|
Our Authorized Share Capital
As of the date of this prospectus, our
board of directors is authorized at any time until June 30, 2016 to increase our share capital by a maximum aggregate amount of
CHF 1,204,706 through the issuance of not more than 3,011,765 shares, which would have to be fully paid-in, with a nominal value
of CHF 0.40 each. Within the limits of Swiss law, the general meeting of shareholders may increase or alter the authorization granted
to the board of directors, within the limits imposed by Swiss Law. See “—Ordinary Capital Increase, Authorized and
Conditional Share Capital.”
Increases in partial amounts are permitted.
The board of directors has the power to determine the type of contributions, the issue price and the date on which the dividend
entitlement starts.
The board of directors is also authorized
to withdraw or limit pre-emptive rights as described above. This authorization is exclusively linked to the particular available
authorized share capital set out in the respective article. If the period to increase the share capital lapses without having been
used by the board of directors, the authorization to withdraw or to limit the pre-emptive rights lapses simultaneously with such
capital.
Our Conditional Share Capital
Conditional Share Capital for Warrants and
Convertible Bonds
Our share capital may be increased by a
maximum aggregate amount of CHF 2,000,000 through the issuance of not more than 5,000,000 common shares, which would have to be
fully paid-in, with a nominal value of CHF 0.40 each, by the exercise of option and conversion rights granted in connection with
warrants and convertible bonds of the Company or one of our subsidiaries. Shareholders will not have pre-emptive rights in such
circumstances. The holders of convertible bonds are entitled to the new shares upon the occurrence of the applicable conversion
feature.
When issuing convertible bonds, the board
of directors is authorized to withdraw or to limit the advance subscription right of shareholders to subscribe to the convertible
bond issuance:
|
·
|
for the purpose of financing or refinancing the acquisition of enterprises, divisions thereof, or of participations or of newly
planned investments of the Company; or
|
|
·
|
if the issuance occurs in domestic or international capital markets including private placements.
|
To the extent that the advance subscription
rights are withdrawn i) the convertible bonds are to be issued at market conditions; ii) the term to exercise the option or conversion
rights may not exceed seven years as of the date of the convertible bond issue; and iii) the exercise price for the new shares
must be determined based on the market conditions at the time of the convertible bond issuance.
Conditional Share Capital for Equity Incentive
Plans
Under our articles of association, our
share capital may, to the exclusion of the pre-emptive rights of shareholders, be increased by a maximum aggregate amount of CHF
577,647.60 through the issuance of not more than 1,444,119 common shares, which would have to be fully paid-in, with a nominal
value of CHF 0.40 each, by the exercise of option or conversion rights that have been granted to employees, members of the board
of directors or consultants of the Company or of one of our subsidiaries through one or more equity incentive plans created by
the board of directors. Of this amount, CHF 371,743.60 or 929,359 common shares remains available, taking into account all options
granted as of the date of this prospectus.
Uncertificated Securities
Our shares are uncertificated securities
(
Wertrechte
, within the meaning of art. 973c of the CO) and, when administered by a financial intermediary (
Verwahrungsstelle
,
within the meaning of the Federal Act on
Intermediated Securities, “FISA”),
qualify as intermediated securities (
Bucheffekten
, within the meaning of the FISA). In accordance with art. 973c of the
CO, we maintain a non-public register of uncertificated securities (
Wertrechtebuch
). We may at any time convert uncertificated
securities into share certificates (including global certificates), one kind of certificate into another, or share certificates
(including global certificates) into uncertificated securities. If registered in our share register, a shareholder may at any time
request from us a written confirmation in respect of the shares. Shareholders are not entitled, however, to request the printing
and delivery of certificates.
General Meeting of Shareholders
Ordinary/extraordinary meetings, powers
The general meeting of shareholders is
our supreme corporate body. Under Swiss law, ordinary and extraordinary general meetings of shareholders may be held. Under Swiss
law, an ordinary general meeting of shareholders must be held annually within six months after the end of a corporation’s
financial year. In our case, this means on or before June 30.
The following powers are vested exclusively
in the general meeting of shareholders:
|
·
|
adopting and amending our articles of association;
|
|
·
|
electing the members of the board of directors, the chairman of the board of directors, the members of the compensation committee,
the auditors and the independent proxy;
|
|
·
|
approving the annual report, the annual statutory financial statements and the consolidated financial statements, and deciding
on the allocation of profits as shown on the balance sheet, in particular with regard to dividends and bonus payments to members
of the board of directors;
|
|
·
|
approving the compensation of members of the board of directors and executive management, which under Swiss law is not necessarily
limited to the executive officers;
|
|
·
|
discharging the members of the board of directors and executive management from liability with respect to their tenure in the
previous financial year;
|
|
·
|
dissolving the Company with or without liquidation;
|
|
·
|
deciding matters reserved to the general meeting of shareholders by law or our articles of association or that are presented
to it by the board of directors.
|
An extraordinary general meeting of shareholders
may be called by a resolution of the board of directors or, under certain circumstances, by the Company’s auditor, liquidator
or the representatives of convertible bond holders, if any. In addition, the board of directors is required to convene an extraordinary
general meeting of shareholders if shareholders representing at least ten percent of the share capital request such general meeting
of shareholders in writing. Such request must set forth the items to be discussed and the proposals to be acted upon. The board
of directors must convene an extraordinary general meeting of shareholders and propose financial restructuring measures if, based
on the Company’s stand-alone annual statutory balance sheet, half of our share capital and reserves are not covered by our
assets.
Voting and Quorum Requirements
Shareholder resolutions and elections (including
elections of members of the board of directors) require the affirmative vote of the absolute majority of shares represented at
the general meeting of shareholders, unless otherwise stipulated by law.
A resolution of the general meeting of
the shareholders passed by two-thirds of the shares represented at the meeting, and the absolute majority of the nominal value
of the shares represented is required for:
|
·
|
amending the Company’s corporate purpose;
|
|
·
|
creating or cancelling shares with preference rights or amending rights attached to such shares;
|
|
·
|
cancelling or amending the transfer restrictions of registered shares;
|
|
·
|
creating authorized or conditional share capital;
|
|
·
|
increasing the share capital out of equity, against contributions in kind or for the purpose of acquiring specific assets and
granting specific benefits;
|
|
·
|
limiting or suppressing shareholder’s pre-emptive rights;
|
|
·
|
dissolving or liquidating the Company.
|
The same voting requirements apply to resolutions
regarding transactions among corporations based on Switzerland’s Federal Act on Mergers, Demergers, Transformations and the
Transfer of Assets, or the Merger Act (including a merger, demerger or conversion of a corporation) see “—Compulsory
Acquisitions; Appraisal Rights.”
In accordance with Swiss law and generally
accepted business practices, our articles of association do not provide quorum requirements generally applicable to general meetings
of shareholders. To this extent, our practice varies from the requirement of Nasdaq Listing Rule 5620(c), which requires an issuer
to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding
voting stock.
Notice
General meetings of shareholders must be
convened by the board of directors at least twenty days before the date of the meeting. The general meeting of shareholders is
convened by way of a notice appearing in our official publication medium, currently the Swiss Official Gazette of Commerce. Registered
shareholders may also be informed by ordinary mail. The notice of a general meeting of shareholders must state the items on the
agenda, the proposals to be acted upon and, in case of elections, the names of the nominated candidates. Except in the limited
circumstances listed below, a resolution may not be passed at a general meeting without proper notice. This limitation does not
apply to proposals to convene an extraordinary general meeting of shareholders or to initiate a special investigation. No previous
notification is required for proposals concerning items included in the agenda or for debates that do not result in a vote. The
notice period for a general meeting of shareholders may be waived if all shareholders are present at such meeting.
Agenda Requests
Pursuant to Swiss law, one or more shareholders
whose combined shareholdings represent the lower of (i) one tenth of the share capital or (ii) an aggregate nominal value of at
least CHF 1,000,000, may request that an item be included in the agenda for an ordinary general meeting of shareholders. To be
timely, the shareholder’s request must be received by us at least 45 calendar days in advance of the meeting. The request
must be made in writing and contain, for each of the agenda items, the following information:
|
·
|
a brief description of the business desired to be brought before the ordinary general meeting of shareholders and the reasons
for conducting such business at the ordinary general meeting of shareholders;
|
|
·
|
the name and address, as they appear in the share register, of the shareholder proposing such business; and
|
|
·
|
all other information required under the applicable laws and stock exchange rules.
|
Our business report, the compensation report
and the auditor’s report must be made available for inspection by the shareholders at our registered office no later than
20 days prior to the general meeting of shareholders. Shareholders of record may be notified of this in writing.
Voting Rights
Each of our shares entitles a holder to
one vote, regardless of its nominal value. The shares are not divisible. The right to vote and the other rights of share ownership
may only be exercised by shareholders (including any nominees) or usufructuaries who are entered in our share register at cut-off
date determined by the board of directors. Those entitled to vote in the general meeting of shareholders may be represented by
the independent proxy holder (annually elected by the general meeting of shareholders), another registered shareholder or third
person with written authorization to act as proxy or the shareholder’s legal representative. The chairman has the power to
decide whether to recognize a power of attorney.
Dividends and Other Distributions
Our board of directors may propose to shareholders
that a dividend or other distribution be paid but cannot itself authorize the distribution. Dividend payments require a resolution
passed by an absolute majority of the shares represented at a general meeting of shareholders. In addition, our auditors must confirm
that the dividend proposal of our board of directors conforms to Swiss statutory law and our articles of association.
Under Swiss law, we may pay dividends only
if we have sufficient distributable profits brought forward from the previous business years (
Gewinnvortrag
), or if we have
distributable reserves (
frei verfügbare Reserven
), each as evidenced by our audited stand-alone statutory balance sheet
prepared pursuant to Swiss law, and after allocations to reserves required by Swiss law and the articles of association have been
deducted. We are not permitted to pay interim dividends out of profit of the current business year.
Distributable reserves are generally booked
either as “free reserves” (
freie Reserven
) or as “reserve from capital contributions” (
Reserven
aus Kapitaleinlagen
). Under the CO, if our general reserves (
allgemeine Reserve
) amount to less than 20% of our share
capital recorded in the commercial register (i.e., 20% of the aggregate nominal value of our issued capital), then at least 5%
of our annual profit must be retained as general reserves. The CO permits us to accrue additional general reserves. Further, a
purchase of our own shares (whether by us or a subsidiary) reduces the distributable reserves in an amount corresponding to the
purchase price of such own shares. Finally, the CO under certain circumstances requires the creation of revaluation reserves which
are not distributable.
Distributions out of issued share capital
(i.e. the aggregate nominal value of our issued shares) are not allowed and may be made only by way of a share capital reduction.
Such a capital reduction requires a resolution passed by an absolute majority of the shares represented at a general meeting of
shareholders. The resolution of the shareholders must be recorded in a public deed and a special audit report must confirm that
claims of our creditors remain fully covered despite the reduction in the share capital recorded in the commercial register. The
share capital may be reduced below CHF 100,000 only if and to the extent that at the same time the statutory minimum share capital
of CHF 100,000 is reestablished by sufficient new fully paid-up capital. Upon approval by the general meeting of shareholders of
the capital reduction, the board of directors must give public notice of the capital reduction resolution in the Swiss Official
Gazette of Commerce three times and notify creditors that they may request, within two months of the third publication, satisfaction
of or security for their claims. The reduction of the share capital may be implemented only after expiration of this time limit.
Our board of directors determines the date
on which the dividend entitlement starts. Dividends are usually due and payable shortly after the shareholders have passed the
resolution approving the payment, but shareholders may also resolve at the ordinary general meeting of shareholders to pay dividends
in quarterly or other installments.
Transfer of Shares
Shares in uncertificated form (
Wertrechte
)
may only be transferred by way of assignment. Shares that constitute intermediated securities (
Bucheffekten
) may only be
transferred when a credit of the relevant intermediated securities to the acquirer’s securities account is made in accordance
with the relevant provisions of the FISA. Article 4 of our articles of association provides that in the case of securities held
with an intermediary such as a registrar, transfer agent, trust corporation, bank or similar entity, any transfer, grant of a security
interest or usufructary right in such intermediated securities and the appurtenant rights associated therewith requires the cooperation
of the intermediary in order for such transfer, grant of a security interest or usufructary right to be valid against us.
Voting rights may be exercised only after
a shareholder has been entered in our share register (
Aktienbuch
) with his or her name and address (in the case of legal
entities, the registered office) as a shareholder with voting rights.
Inspection of Books and Records
Under the CO, a shareholder has a right
to inspect our share register with respect to his own shares and otherwise to the extent necessary to exercise his shareholder
rights. No other person has a right to inspect our share register. Our books and correspondence may be inspected with the express
authorization of the general meeting of shareholders or by resolution of the board of directors and subject to the safeguarding
of our business secrets. See “Comparison of Swiss Law and Delaware Law—Inspection of Books and Records.”
Special Investigation
If the shareholders’ inspection rights
as outlined above prove to be insufficient in the judgment of the shareholder, any shareholder may propose to the general meeting
of shareholders that specific facts be examined by a special commissioner in a special investigation. If the general meeting of
shareholders approves the proposal, we or any shareholder may, within 30 calendar days after the general meeting of shareholders,
request a court sitting in Zug, Switzerland, our registered office, to appoint a special commissioner. If the general meeting of
shareholders rejects the request, one or more shareholders representing at least 10 percent of the share capital or holders of
shares in an aggregate nominal value of at least CHF 2,000,000 may request that the court appoint a special commissioner. The court
will issue such an order if the petitioners can demonstrate that the board of directors, any member of the board of directors or
our executive management infringed the law or our articles of association and thereby caused damages to the Company or the shareholders.
The costs of the investigation would generally be allocated to us and only in exceptional cases to the petitioners.
Compulsory Acquisitions; Appraisal Rights
Business combinations and other transactions
that are governed by the Swiss Merger Act (i.e. mergers, demergers, transformations and certain asset transfers) are binding on
all shareholders. A statutory merger or demerger requires approval of two-thirds of the shares represented at a general meeting
of shareholders and the absolute majority of the nominal value of the shares represented.
Swiss corporations may be acquired by an
acquirer through the direct acquisition of the share capital of the Swiss corporation. The Swiss Merger Act provides for the possibility
of a so-called “cash-out” or “squeeze-out” merger if the acquirer controls 90% of the outstanding shares.
In these limited circumstances, minority shareholders of the corporation being acquired may be compensated in a form other than
through shares of the acquiring corporation (for instance, through cash or securities of a parent corporation of the acquiring
corporation or of another corporation). For business combinations effected in the form of a statutory merger or demerger and subject
to Swiss law, the Swiss Merger Act provides that if equity rights have not been adequately preserved or compensation payments in
the transaction are unreasonable, a shareholder may request the competent court to determine a reasonable amount of compensation.
In addition, under Swiss law, the sale
of “all or substantially all of our assets” by us may require the approval of two-thirds of the number of shares represented
at a general meeting shareholders and the absolute majority of the nominal value of the shares represented. Whether a shareholder
resolution is required depends on the particular transaction, including whether the following test is satisfied:
|
·
|
a core part of the Company’s business is sold without which it is economically impracticable or unreasonable to continue
to operate the remaining business;
|
|
·
|
the Company’s assets, after the divestment, are not invested in accordance with the Company’s statutory business
purpose; and
|
|
·
|
the proceeds of the divestment are not earmarked for reinvestment in accordance with the Company’s business purpose but,
instead, are intended for distribution to the Company’s shareholders or for financial investments unrelated to the Company’s
business.
|
A shareholder of a Swiss corporation participating
in certain major corporate transactions may, under certain circumstances, be entitled to appraisal rights. As a result, such shareholder
may, in addition to the consideration (be it in shares or in cash) receive an additional amount to ensure that the shareholder
receives the fair value of the shares held by the shareholder. Following a statutory merger or demerger, pursuant to the Merger
Act, shareholders
can file an appraisal action against the surviving
company. If the consideration is deemed inadequate, the court will determine an adequate compensation payment.
Board of Directors
Our articles of association provide that
the board of directors shall consist of at least three and not more than nine members.
The members of the board of directors and
the chairman are elected annually by the general meeting of shareholders for a period until the completion of the subsequent ordinary
general meeting of shareholders and are eligible for re-election. Each member of the board of directors must be elected individually.
Unless an exception is granted by the general meeting of shareholders, only persons who have not completed their seventy-fifth
year of age on the election date are eligible for election.
Powers
The board of directors has the following
non-delegable and inalienable powers and duties:
|
·
|
the ultimate direction of the business of the Company and issuing of the relevant directives;
|
|
·
|
laying down the organization of the Company;
|
|
·
|
formulating accounting procedures, financial controls and financial planning, to the extent required for the governance of
the Company;
|
|
·
|
nominating and removing persons entrusted with the management and representation of the Company and regulating the power to
sign for the Company;
|
|
·
|
the ultimate supervision of those persons entrusted with management of the Company, with particular regard to adherence to
law, our articles of association, and regulations and directives of the Company;
|
|
·
|
issuing the annual report and the compensation report, and preparing for the general meeting of shareholders and carrying out
its resolutions; and
|
|
·
|
informing the court in case of over-indebtedness.
|
The board of directors may, while retaining
such non-delegable and inalienable powers and duties, delegate some of its powers, in particular direct management, to a single
or to several of its members, managing directors, committees or to third parties who need be neither members of the board of directors
nor shareholders. Pursuant to Swiss law and Article 13 of our articles of association, details of the delegation and other procedural
rules such as quorum requirements must be set in the organizational rules issued by the board of directors.
Indemnification of Executive Management and
Directors
Subject to Swiss law, Article 17 of our
articles of association provides for indemnification of the existing and former members of the board of directors, executive management
and their heirs, executors and administrators, against liabilities arising in connection with the performance of their duties in
such capacity, and permits us to advance the expenses of defending any act, suit or proceeding to our directors and executive management.
In addition, under general principles of
Swiss employment law, an employer may be required to indemnify an employee against losses and expenses incurred by such employee
in the proper execution of their duties under the employment agreement with the employer. See “Comparison of Swiss Law and Delaware Law—Indemnification of directors and executive management and limitation
of liability.”
We have entered into indemnification agreements
with each of the members of our board of directors and executive management. The indemnification agreements and our articles of
association require us to indemnify our directors and executive officers to the fullest extent permitted by law.
Conflict of Interest, Management Transactions
Swiss law does not have a general provision
regarding conflicts of interest. However, the CO contains a provision that requires our directors and executive management to safeguard
the Company’s interests and imposes a duty of loyalty and duty of care on our directors and executive management. This rule
is generally understood to disqualify directors and executive management from participation in decisions that directly affect them.
Our directors and executive officers are personally liable to us for breach of these provisions. In addition, Swiss law contains
provisions under which directors and all persons engaged in the Company’s management are liable to the Company, each shareholder
and the Company’s creditors for damages caused by an intentional or negligent violation of their duties. Furthermore, Swiss
law contains a provision under which payments made to any of the Company’s shareholders or directors or any person associated
with any such shareholder or director, other than payments made at arm’s length, must be repaid to the Company if such shareholder
or director acted in bad faith.
Our board of directors has adopted a Code
of Business Conduct and Ethics that covers a broad range of matters, including the handling of conflicts of interest.
Principles of the Compensation of the
Board of Directors and the Executive Management
Pursuant to Swiss law, beginning at our
first annual meeting as a public company in 2015 our shareholders must annually approve the compensation of the board of directors
and the persons whom the board of directors has, fully or partially, entrusted with the management of the Company. The board of
directors must issue, on an annual basis, a written compensation report that must be reviewed together with a report on our business
by our auditor. The compensation report must disclose all compensation, loans and other forms of indebtedness granted by the Company,
directly or indirectly, to current or former members of the board of directors and executive management to the extent related to
their former role within the Company or not on customary market terms.
The disclosure concerning compensation,
loans and other forms of indebtedness must include the aggregate amount for the board of directors and the executive management
as well as the particular amount for each member of the board of directors and executive officer, specifying the name and function
of each respective person.
Certain forms of compensation are prohibited
for members of our board of directors and executive management, such as:
|
·
|
severance payments provided for either contractually or in the articles of association (compensation due until the termination
of a contractual relationship does not qualify as severance payment);
|
|
·
|
incentive fees for the acquisition or transfer of corporations or parts thereof by the Company or by companies being, directly
or indirectly, controlled by us;
|
|
·
|
loans, other forms of indebtedness, pension benefits not based on occupational pension schemes and performance-based compensation
not provided for in the articles of association; and
|
|
·
|
equity securities and conversion and option rights awards not provided for in the articles of association.
|
Compensation to members of the board of
directors and executive management for activities in entities that are, directly or indirectly, controlled by the Company is prohibited
if the compensation (i) would have been prohibited if it was paid directly by the Company, (ii) is not provided for in the articles
of association or (iii) has not been approved by the general meeting of shareholders.
The general meeting of shareholders annually
votes on the proposals of the board of directors with respect to:
|
·
|
the maximum aggregate amount of compensation of the board of directors for the subsequent term of office; and
|
|
·
|
the maximum aggregate amount of compensation of the executive management for the subsequent financial year.
|
The board of directors may submit for approval
at the general meeting of shareholders deviating or additional proposals relating to the same or different periods.
In the event that at the general meeting
of shareholders the shareholders do not approve a proposal of the board of directors, the board of directors must form a new proposal
for the maximum aggregate compensation and the particular compensation for each individual, taking into account all relevant factors,
and submit the new proposal for approval by the same general meeting of shareholders, at a subsequent extraordinary general meeting
or the next ordinary general meeting of shareholders.
In addition to fixed compensation, members
of the board of directors and executive management may be paid variable compensation, depending on the achievement of certain performance
criteria. The performance criteria may include individual targets, targets of the Company or parts thereof and targets in relation
to the market, other companies or comparable benchmarks, taking into account the position and level of responsibility of the recipient
of the variable compensation. The board of directors or, where delegated to it, the compensation committee shall determine the
relative weight of the performance criteria and the respective target values.
Compensation may be paid or granted in
the form of cash, shares, financial instruments, in kind, or in the form of other types of benefits. The board of directors or,
where delegated to it, the compensation committee shall determine grant, vesting, exercise and forfeiture conditions.
Borrowing Powers
Neither Swiss law nor our articles of association
restrict in any way our power to borrow and raise funds. The decision to borrow funds is made by or under the direction of our
board of directors, and no approval by the shareholders is required in relation to any such borrowing.
Repurchases of Shares and Purchases of
Own Shares
The CO limits our right to purchase and
hold our own shares. We and our subsidiaries may purchase shares only if and to the extent that (i) we have freely distributable
reserves in the amount of the purchase price; and (ii) the aggregate nominal value of all shares held by us does not exceed 10
percent of our share capital. Pursuant to Swiss law, where shares are acquired in connection with a transfer restriction set out
in the articles of association, the foregoing upper limit is 20 percent. We currently do not have any transfer restriction in our
articles of association. If we own shares that exceed the threshold of 10 percent of our share capital, the excess must be sold
or cancelled by means of a capital reduction within two years.
Shares held by us or our subsidiaries are
not entitled to vote at the general meeting of shareholders but are entitled to the economic benefits applicable to the shares
generally, including dividends and pre-emptive rights in the case of share capital increases.
In addition, selective share repurchases
are only permitted under certain circumstances. Within these limitations, as is customary for Swiss corporations, we may purchase
and sell our own shares from time to time in order to meet imbalances of supply and demand, to provide liquidity and to even out
variances in the market price of shares.
Notification and Disclosure of Substantial
Share Interests
The disclosure obligations generally applicable
to shareholders of Swiss corporations under the Swiss Act on Stock Exchanges and Securities Trading do not apply to us since our
shares are not listed on a Swiss exchange.
Pursuant to art. 663c of the CO, Swiss
corporations whose shares are listed on a stock exchange must disclose their significant shareholders and their shareholdings in
the notes to their balance sheet, where this information is known or ought to be known. Significant shareholders are defined as
shareholders and groups of shareholders linked through voting rights who hold more than five percent of all voting rights.
Stock Exchange Listing
Our common shares are listed on the Nasdaq
Global Market under the symbol “EARS.”
The Depository Trust Company
Initial settlement of any common shares
to be issued pursuant to this prospectus will take place through The Depository Trust Company, or DTC, in accordance with its customary
settlement procedures for equity securities. Each person owning common shares held through DTC must rely on the procedures thereof
and on institutions that have accounts therewith to exercise any rights of a holder of the shares.
Transfer Agent and Registrar of Shares
Our share register is currently kept by
American Stock Transfer & Trust Company, LLC., which acts as transfer agent and registrar. The share register reflects only
record owners of our shares. Swiss law does not recognize fractional share interests.
Comparison
of Swiss Law and Delaware Law
The Swiss laws applicable to Swiss corporations
and their shareholders differ from laws applicable to U.S. corporations and their shareholders. The following table summarizes
significant differences in shareholder rights between the provisions of the Swiss Code of Obligations (
Schweizerisches Obligationenrecht
)
and the Swiss Ordinance against excessive compensation in listed stock corporations applicable to our company and the Delaware
General Corporation Law applicable to companies incorporated in Delaware and their shareholders. Please note that this is only
a general summary of certain provisions applicable to companies in Delaware. Certain Delaware companies may be permitted to exclude
certain of the provisions summarized below in their charter documents.
DELAWARE
CORPORATE LAW
|
|
SWISS
CORPORATE LAW
|
Mergers and similar arrangements
|
Under the Delaware General Corporation Law, with certain exceptions, a merger, consolidation, sale, lease or transfer of all or substantially all of the assets of a corporation must be approved by the board of directors and a majority of the outstanding shares entitled to vote thereon. A shareholder of a Delaware corporation participating in certain major corporate transactions may, under certain circumstances, be entitled to appraisal rights pursuant to which such shareholder may receive cash in the amount of the fair value of the shares held by such shareholder (as determined by a court) in lieu of the consideration such shareholder would otherwise receive in the transaction. The Delaware General Corporation Law also provides that a parent corporation, by resolution of its board of directors, may merge with any subsidiary, of which it owns at least 90.0% of each class of capital stock without a vote by the shareholders of such subsidiary. Upon any such merger, dissenting shareholders of the subsidiary would have appraisal rights.
|
|
Under Swiss law, with certain exceptions, a merger or a division of the corporation or a sale of all or substantially all of the assets of a corporation must be approved by two-thirds of the shares represented at the respective general meeting of shareholders as well as the absolute majority of the share capital represented at such shareholders’ meeting. The articles of association may increase the voting threshold. A shareholder of a Swiss corporation participating in a statutory merger or demerger pursuant to the Swiss Merger Act can file an appraisal right lawsuit against the surviving company. As a result, if the consideration is deemed “inadequate,” such shareholder may, in addition to the consideration (be it in shares or in cash) receive an additional amount to ensure that such shareholder receives the fair value of the shares held by such shareholder. Swiss law also provides that a parent corporation, by resolution of its board of directors, may merge with any subsidiary, of which it owns at least 90.0% of the shares without a vote by shareholders of such subsidiary, if the shareholders of the subsidiary are offered the payment of the fair value in cash as an alternative to shares.
|
Shareholders’ suits
|
Class actions and derivative actions generally are available to shareholders of a Delaware corporation for, among other things, breach of fiduciary duty, corporate waste and actions not taken in accordance with
|
|
Class actions and derivative actions as such are not available under Swiss law. Nevertheless, certain actions may have a similar effect. A shareholder is entitled to bring suit against directors for breach of, among other
|
DELAWARE
CORPORATE LAW
|
|
SWISS
CORPORATE LAW
|
applicable law. In such actions, the court has discretion to permit the winning party to recover attorneys’ fees incurred in connection with such action.
|
|
things, their fiduciary duties and claim the payment of the company’s damages to the corporation. Likewise, an appraisal lawsuit won by a shareholder will indirectly compensate all shareholders. Under Swiss law, the winning party is generally entitled to recover attorneys’ fees incurred in connection with such action, provided, however, that the court has discretion to permit the shareholder whose claim has been dismissed to recover attorneys’ fees incurred to the extent he acted in good faith.
|
Shareholder vote on board and management compensation
|
Under the Delaware General Corporation Law, the board of directors has the authority to fix the compensation of directors, unless otherwise restricted by the certificate of incorporation or bylaws.
|
|
Pursuant to the Swiss Ordinance against excessive compensation in listed stock corporations, the general meeting of shareholders has the non-transferable right, amongst others, to vote on the compensation due to the board of directors, executive management and advisory boards.
|
Annual vote on board renewal
|
Unless directors are elected by written consent in lieu of an
annual meeting, directors are elected in an annual meeting of stockholders on a date and at a time designated by or in the manner
provided in the bylaws. Re-election is possible.
Classified boards are permitted.
|
|
The general meeting of shareholders elects annually (i.e. until the following general meeting of shareholders) the members of the board of directors and the members of the compensation committee individually for a term of office of one year. Re-election is possible.
|
Indemnification of directors and executive management and limitation of liability
|
The Delaware General Corporation Law provides that a certificate
of incorporation may contain a provision eliminating or limiting the personal liability of directors (but not other controlling
persons) of the corporation for monetary damages for breach of a fiduciary duty as a director, except no provision in the certificate
of incorporation may eliminate or limit the liability of a director for:
·
any
breach of a director’s duty of loyalty to the corporation or its shareholders;
·
acts
or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;
·
statutory
liability for unlawful payment of dividends or unlawful stock purchase or redemption; or
·
any
transaction from which the director derived an improper personal benefit.
A Delaware corporation may indemnify any person who was or is
a party or is threatened to be made a party to
|
|
Under Swiss corporate law, an indemnification of a director
or member of the executive management in relation to potential personal liability is not effective to the extent the director or
member of the executive management intentionally or negligently violated his or her corporate duties towards the corporation (certain
views advocate that at least a grossly negligent violation is required to exclude the indemnification). Most violations of corporate
law are regarded as violations of duties towards the corporation rather than towards the shareholders. In addition, indemnification
of other controlling persons is not permitted under Swiss corporate law, including shareholders of the corporation.
Nevertheless, a corporation may enter into and pay for directors’
and officers’ liability insurance which typically covers negligent acts as well.
|
DELAWARE
CORPORATE LAW
|
|
SWISS
CORPORATE LAW
|
any proceeding, other than an action by or on behalf of the corporation, because the person is or was a director or officer, against liability incurred in connection with the proceeding if the director or officer acted in good faith and in a manner reasonably believed to be in, or not opposed to, the best interests of the corporation; and the director or officer, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.
|
|
|
Unless ordered by a court, any foregoing indemnification is
subject to a determination that the director or officer has met the applicable standard of conduct:
·
by
a majority vote of the directors who are not parties to the proceeding, even though less than a quorum;
·
by
a committee of directors designated by a majority vote of the eligible directors, even though less than a quorum;
·
by
independent legal counsel in a written opinion if there are no eligible directors, or if the eligible directors so direct; or
·
by
the shareholders.
Moreover, a Delaware corporation may not indemnify a director
or officer in connection with any proceeding in which the director or officer has been adjudged to be liable to the corporation
unless and only to the extent that the court determines that, despite the adjudication of liability but in view of all the circumstances
of the case, the director or officer is fairly and reasonably entitled to indemnity for those expenses which the court deems proper.
|
|
|
Directors’ fiduciary duties
|
A director of a Delaware corporation has a fiduciary duty to
the corporation and its shareholders. This duty has two components:
·
the
duty of care; and
·
the
duty of loyalty.
The duty of care requires that a director act in good faith,
with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform
himself of, and disclose to shareholders, all material information reasonably available regarding a significant transaction. The
duty of loyalty requires that a director act in a manner he
|
|
A director of a Swiss corporation has a fiduciary duty to the
corporation only. This duty has two components:
·
the
duty of care; and
·
the
duty of loyalty.
The duty of care requires that a director act in good faith,
with the care that an ordinarily prudent director would exercise under similar circumstances. Under this duty, a director must
inform himself of, and disclose, all material information reasonably available regarding a significant transaction.
The duty of loyalty requires that a director act in a manner
he reasonably believes to be in the best interests
|
DELAWARE
CORPORATE LAW
|
|
SWISS
CORPORATE LAW
|
reasonably believes to be in the best interests of the corporation.
He must not use his corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates
that the best interest of the corporation and its shareholders take precedence over any interest possessed by a director, officer
or controlling shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have
been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation.
However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties.
Should such evidence be presented concerning a transaction by
a director, a director must prove the procedural fairness of the transaction, and that the transaction was of fair value to the
corporation.
|
|
of the corporation. He must not use his corporate position for
personal gain or advantage. This duty prohibits in principle self-dealing by a director and mandates that the best interest of
the corporation take precedence over any interest possessed by a director or officer.
The burden of proof for a violation of these duties is with
the corporation or with the shareholder bringing a suit against the director.
Directors also have an obligation to treat shareholders equally
proportionate to their share ownership.
|
Shareholder action by written consent
|
A Delaware corporation may, in its certificate of incorporation, eliminate the right of shareholders to act by written consent.
|
|
Shareholders of a Swiss corporation may only exercise their voting rights in a general meeting of shareholders and may not act by written consent.
|
Shareholder proposals
|
A shareholder of a Delaware corporation has the right to put any proposal before the annual meeting of shareholders, provided it complies with the notice provisions in the governing documents. A special meeting may be called by the board of directors or any other person authorized to do so in the governing documents, but shareholders may be precluded from calling special meetings.
|
|
At any general meeting of shareholders any shareholder may put
proposals to the meeting if the proposal is part of an agenda item. Unless the articles of association provide for a lower threshold
or for additional shareholders’ rights:
·
one
or several shareholders representing 10.0% of the share capital may ask that a general meeting of shareholders be called for specific
agenda items and specific proposals; and
·
one
or several shareholders representing 10.0% of the share capital or CHF 1.0 million of nominal share capital may ask that an agenda
item including a specific proposal be put on the agenda for a regularly scheduled general meeting of shareholders, provided such
request is made with appropriate notice.
Any shareholder can propose candidates for election as directors
without prior written notice.
In addition, any shareholder is entitled, at a general meeting
of shareholders and without advance notice, to (i) request information from the Board on the affairs of the company (note, however,
that the right to obtain such information is limited), (ii) request information from the auditors on the methods and results of
their audit, and (iii) request, under certain circumstances and subject to
|
DELAWARE
CORPORATE LAW
|
|
SWISS
CORPORATE LAW
|
|
|
certain conditions, a special audit.
|
Cumulative voting
|
Under the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the corporation’s certificate of incorporation provides for it.
|
|
Cumulative voting is not permitted under Swiss corporate law. Pursuant to Swiss law, shareholders can vote for each proposed candidate, but they are not allowed to cumulate their votes for single candidates. An annual individual election of all members of the board of directors for a term of office of one year (i.e. until the following annual general meeting) is mandatory for listed companies.
|
Removal of directors
|
A Delaware corporation with a classified board may be removed only for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise.
|
|
A Swiss corporation may remove, with or without cause, any director at any time with a resolution passed by an absolute majority of the shares represented at a general meeting of shareholders. The articles of association may provide for a qualified majority for the removal of a director.
|
Transactions with interested shareholders
|
The Delaware General Corporation Law generally prohibits a Delaware corporation from engaging in certain business combinations with an “interested shareholder” for three years following the date that such person becomes an interested shareholder. An interested shareholder generally is a person or group who or which owns or owned 15.0% or more of the corporation’s outstanding voting stock within the past three years.
|
|
No such rule applies to a Swiss corporation.
|
Dissolution; Winding up
|
Unless the board of directors of a Delaware corporation approves the proposal to dissolve, dissolution must be approved by shareholders holding 100.0% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation’s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board.
|
|
A dissolution and winding up of a Swiss corporation requires the approval by two-thirds of the shares represented as well as the absolute majority of the nominal value of the share capital represented at a general meeting of shareholders passing a resolution on such dissolution and winding up. The articles of association may increase the voting thresholds required for such a resolution.
|
Variation of rights of shares
|
A Delaware corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise.
|
|
A Swiss corporation may modify the rights of a category of shares with (i) a resolution passed by an absolute majority of the shares represented at the general meeting of shareholders and (ii) a resolution passed by an absolute majority of the shares represented at the special meeting of the affected preferred shareholders. Shares that are granted more voting power are not regarded a special class for these purposes.
|
DELAWARE
CORPORATE LAW
|
SWISS
CORPORATE LAW
|
Amendment of governing documents
|
A Delaware corporation’s governing documents may be amended with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise.
|
|
The articles of association of a Swiss corporation may be amended with a resolution passed by an absolute majority of the shares represented at such meeting, unless otherwise provided in the articles of association. There are a number of resolutions, such as an amendment of the stated purpose of the corporation and the introduction of authorized and conditional capital, that require the approval by two-thirds of the votes and an absolute majority of the nominal value of the shares represented at a shareholders’ meeting. The articles of association may increase the voting thresholds.
|
Inspection of Books and Records
|
Shareholders of a Delaware corporation, upon written demand under oath stating the purpose thereof, have the right during the usual hours for business to inspect for any proper purpose, and to obtain copies of list(s) of shareholders and other books and records of the corporation and its subsidiaries, if any, to the extent the books and records of such subsidiaries are available to the corporation.
|
|
Shareholders of a Swiss corporation may only inspect books and records if the general meeting of shareholders or the board of directors approved such inspection. The inspection right is limited in scope and only extends to information required for the exercise of shareholder rights and does not extend to confidential information. The right to inspect the share register is limited to the right to inspect that shareholder’s own entry in the share register.
|
Payment of dividends
|
The board of directors may approve a dividend without shareholder
approval. Subject to any restrictions contained in its certificate of incorporation, the board may declare and pay dividends upon
the shares of its capital stock either:
·
out
of its surplus, or
·
in
case there is no such surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding
fiscal year.
Stockholder approval is required to authorize capital stock
in excess of that provided in the charter. Directors may issue authorized shares without stockholder approval.
|
|
Dividend payments are subject to the approval of the general
meeting of shareholders. The board of directors may propose to shareholders that a dividend shall be paid but cannot itself authorize
the distribution.
Payments out of the Company’s share capital (in other
words, the aggregate nominal value of the Company’s registered share capital) in the form of dividends are not allowed and
may be made by way of a capital reduction only. Dividends may be paid only from the profits brought forward from the previous business
years or if the Company has distributable reserves, each as will be presented on the Company’s audited annual stand-alone
balance sheet. The dividend may be determined only after the allocations to reserves required by the law and the articles of association
have been deducted.
|
Creation and issuance of new shares
|
All creation of shares require the board of directors to adopt a resolution or resolutions, pursuant to authority expressly vested in the board of directors by the provisions of the company’s certificate of incorporation.
|
|
All creation of shares require a shareholders’ resolution. Authorized shares can be, once created by shareholders’ resolution, issued by the board of directors (subject to fulfillment of the authorization). Conditional shares are created and issued through the exercise of options and conversion rights related to debt instruments issued by the board of directors or such rights issued to employees.
|
Description
of Debt Securities
The debt securities will be our direct
general obligations. The debt securities will be either senior debt securities or subordinated debt securities and may be secured
or unsecured and may be convertible into other securities, including our common shares. The debt securities will be issued under
one or more separate indentures between our company and a financial institution that will act as trustee. Senior debt securities
will be issued under a senior indenture. Subordinated debt securities will be issued under a subordinated indenture. Each of the
senior indenture and the subordinated indenture is referred to individually as an indenture and collectively as the indentures.
Each of the senior debt trustee and the subordinated debt trustee is referred to individually as a trustee and collectively as
the trustees. The material terms of any indenture will be set forth in the applicable prospectus supplement.
We have summarized certain terms and provisions
of the indentures. The summary is not complete. The indentures are subject to and governed by the Trust Indenture Act of 1939,
as amended. The senior indenture and subordinated indenture are substantially identical, except for the provisions relating to
subordination.
Neither indenture will limit the amount
of debt securities that we may issue. We may issue debt securities up to an aggregate principal amount as we may authorize from
time to time. The applicable prospectus supplement will describe the terms of any debt securities being offered. These terms will
include some or all of the following:
|
·
|
classification as senior or subordinated debt securities;
|
|
·
|
ranking of the specific series of debt securities relative to other outstanding indebtedness, including subsidiaries’
debt;
|
|
·
|
if the debt securities are subordinated, the aggregate amount of outstanding indebtedness, as of a recent date, that is senior
to the subordinated securities, and any limitation on the issuance of additional senior indebtedness;
|
|
·
|
the designation, aggregate principal amount and authorized denominations;
|
|
·
|
the date or dates on which the principal of the debt securities may be payable;
|
|
·
|
the rate or rates (which may be fixed or variable) per annum at which the debt securities shall bear interest, if any;
|
|
·
|
the date or dates from which such interest shall accrue, on which such interest shall be payable, and on which a record shall
be taken for the determination of holders of the debt securities to whom interest is payable;
|
|
·
|
the place or places where the principal and interest shall be payable;
|
|
·
|
our right, if any, to redeem the debt securities, in whole or in part, at our option and the period or periods within which,
the price or prices at which and any terms and conditions upon which such debt securities may be so redeemed, pursuant to any sinking
fund or otherwise;
|
|
·
|
our obligation, if any, of the Company to redeem, purchase or repay any debt securities pursuant to any mandatory redemption,
sinking fund or other provisions or at the option of a holder of the debt securities;
|
|
·
|
if other than denominations of $2,000 and any higher integral multiple of $1,000, the denominations in which the debt securities
will be issuable;
|
|
·
|
if other than the currency of the United States, the currency or currencies, in which payment of the principal and interest
shall be payable;
|
|
·
|
whether the debt securities will be issued in the form of global securities;
|
|
·
|
provisions, if any, for the defeasance of the debt securities;
|
|
·
|
any U.S. federal income tax consequences; and
|
|
·
|
other specific terms, including any deletions from, modifications of or additions to the events of default or covenants described
below or in the applicable indenture.
|
Senior Debt
We will issue under the senior indenture
the debt securities that will constitute part of our senior debt. These senior debt securities will rank equally and pari passu
with all our other unsecured and unsubordinated debt.
Subordinated Debt
We will issue under the subordinated indenture
the debt securities that will constitute part of our subordinated debt. These subordinated debt securities will be subordinate
and junior in right of payment, to the extent and in the manner set forth in the subordinated indenture, to all our “senior
indebtedness.” “Senior indebtedness” is defined in the subordinated indenture and generally includes obligations
of, or guaranteed by, us for borrowed money, or as evidenced by bonds, debentures, notes or other similar instruments, or in respect
of letters of credit or other similar instruments, or to pay the deferred purchase price of property or services, or as a lessee
under capital leases, or as secured by a lien on any asset of ours. “Senior indebtedness” does not include the subordinated
debt securities or any other obligations specifically designated as being subordinate in right of payment to, or pari passu with,
the subordinated debt securities. In general, the holders of all senior indebtedness are first entitled to receive payment in full
of such senior indebtedness before the holders of any of the subordinated debt securities are entitled to receive a payment on
account of the principal or interest on the indebtedness evidenced by the subordinated debt securities in certain events. These
events include:
|
·
|
subject to Swiss law, any insolvency or bankruptcy proceedings, or any receivership, dissolution, winding up, total or partial
liquidation, reorganization or other similar proceedings in respect of us or a substantial part of our property, whether voluntary
or involuntary;
|
|
·
|
(i) a default having occurred with respect to the payment of principal or interest on or other monetary amounts due and payable
with respect to any senior indebtedness or (ii) an event of default (other than a default described in clause (i) above) having
occurred with respect to any senior indebtedness that permits the holder or holders of such senior indebtedness to accelerate the
maturity of such senior indebtedness. Such a default or event of default must have continued beyond the period of grace, if any,
provided in respect of such default or event of default, and such a default or event of default shall not have been cured or waived
or shall not have ceased to exist; and
|
|
·
|
the principal of, and accrued interest on, any series of the subordinated debt securities having been declared due and payable
upon an event of default pursuant to the subordinated indenture. This declaration must not have been rescinded and annulled as
provided in the subordinated indenture.
|
Authentication and Delivery
We will deliver the debt securities to
the trustee for authentication, and the trustee will authenticate and deliver the debt securities upon our written order.
Events of Default
When we use the term “Event of Default”
in the indentures with respect to the debt securities of any series, set forth below are some examples of what we mean:
|
(1)
|
default in the payment of the principal on the debt securities when it becomes due and payable at maturity or otherwise;
|
|
(2)
|
default in the payment of interest on the debt securities when it becomes due and payable, and such default continues for a
period of 30 days;
|
|
(3)
|
default in the performance, or breach, of any covenant in the indenture (other than defaults specified in clauses (1) or (2)
above) and the default or breach continues for a period of 90 consecutive days or more after written notice to us by the trustee
or to us and the trustee by the holders of 25% or more in aggregate principal amount of the outstanding debt securities of all
series affected thereby;
|
|
(4)
|
the occurrence of certain events of bankruptcy, insolvency, or similar proceedings with respect to us or any substantial part
of our property; or
|
|
(5)
|
any other Events of Default that may be set forth in the applicable prospectus supplement.
|
If an Event of Default (other than an Event
of Default specified in clause (4) above) with respect to the debt securities of any series then outstanding occurs and is continuing,
then either the trustee or the holders of not less than 25% in principal amount of the securities of all such series then outstanding
in respect of which an Event of Default has occurred may by notice in writing to us declare the entire principal amount of all
debt securities of the affected series, and accrued interest, if any, to be due and payable immediately, and upon any such declaration
the same shall become immediately due and payable.
If an Event of Default described in clause
(4) above occurs and is continuing, then the principal amount of all the debt securities then outstanding and accrued interest
shall be and become due immediately and payable without any declaration, notice or other action by any holder of the debt securities
or the trustee.
The trustee will, within 90 days after
the occurrence of any default actually known to it, give notice of the default to the holders of the debt securities of that series,
unless the default was already cured or waived. Unless there is a default in paying principal or interest when due, the trustee
can withhold giving notice to the holders if it determines in good faith that the withholding of notice is in the interest of the
holders.
Satisfaction, Discharge and Defeasance
We may discharge our obligations under
each indenture, except as to:
|
·
|
the rights of registration of transfer and exchange of debt securities, and our right of optional redemption, if any;
|
|
·
|
substitution of mutilated, defaced, destroyed, lost or stolen debt securities;
|
|
·
|
the rights of holders of the debt securities to receive payments of principal and interest;
|
|
·
|
the rights, obligations and immunities of the trustee; and
|
|
·
|
the rights of the holders of the debt securities as beneficiaries with respect to the property deposited with the trustee payable
to them (as described below);
|
when:
|
·
|
all debt securities of any series issued that have been authenticated and delivered have been delivered by us to the trustee
for cancellation; or
|
|
·
|
all the debt securities of any series issued that have not been delivered by us to the trustee for cancellation have become
due and payable or will become due and payable within one year or are to be called for redemption within one year under arrangements
satisfactory to the trustee for the giving of notice of redemption by such trustee in our name and at our expense, and we have
irrevocably deposited or caused to be deposited with the trustee as trust funds the entire amount sufficient to pay at maturity
or upon redemption all debt securities of such series not delivered to the trustee for cancellation, including principal and interest
due or to become due on or prior to such date of maturity or redemption;
|
|
·
|
we have paid or caused to be paid all other sums then due and payable under such indenture; and
|
|
·
|
we have delivered to the trustee an officers’ certificate and an opinion of counsel, each stating that all conditions
precedent under such indenture relating to the satisfaction and discharge of such indenture have been complied with.
|
In addition, unless the applicable prospectus
supplement and supplemental indenture otherwise provide, we may elect either (i) to have our obligations under each indenture discharged
with respect to the outstanding debt securities of any series (“legal defeasance”) or (ii) to be released from our
obligations under each indenture with respect to certain covenants applicable to the outstanding debt securities of any series
(“covenant defeasance”). Legal defeasance means that we will be deemed to have paid and discharged the entire indebtedness
represented by the outstanding debt securities of such series under such indenture and covenant defeasance means that we will no
longer be required to comply with the obligations with respect to such covenants (and an omission to comply with such obligations
will not constitute a default or event of default).
In order to exercise legal defeasance or
covenant defeasance with respect to outstanding debt securities of any series:
|
·
|
we must irrevocably have deposited or caused to be deposited with the trustee as trust funds in trust for the purpose of making
the following payments, specifically pledged as security for, and dedicated solely to the benefits of the holders of the debt securities
of a series:
|
|
·
|
U.S. government obligations; or
|
|
·
|
a combination of money and U.S. government obligations,
|
in each case sufficient without reinvestment, in the
written opinion of a nationally recognized firm of independent public accountants, to pay and discharge, and which shall be applied
by the trustee to pay and discharge, all of the principal and interest at due date or maturity or if we have made irrevocable arrangements
satisfactory to the trustee for the giving of notice of redemption by the trustee, the redemption date;
|
·
|
we have delivered to the trustee an opinion of counsel stating that, under then applicable U.S. federal income tax law, the
holders of the debt securities of that series will not recognize gain or loss for U.S. federal income tax purposes as a result
of the defeasance and will be subject to the same federal income tax as would be the case if the defeasance did not occur;
|
|
·
|
no default relating to bankruptcy or insolvency and, in the case of a covenant defeasance, no other default has occurred and
is continuing at any time;
|
|
·
|
if at such time the debt securities of such series are listed on a national securities exchange, we have delivered to the trustee
an opinion of counsel to the effect that the debt securities of such series will not be delisted as a result of such defeasance;
and
|
|
·
|
we have delivered to the trustee an officers’ certificate and an opinion of counsel stating that all conditions precedent
with respect to the defeasance have been complied with.
|
We are required to furnish to each trustee
an annual statement as to compliance with all conditions and covenants under the indenture.
Description
of Warrants
We may issue warrants to purchase debt
securities, common shares or other securities. We may issue warrants independently or together with other securities. Warrants
sold with other securities may be attached to or separate from the other securities. We will issue warrants under one or more warrant
agreements between our company and a warrant agent that we will name in the applicable prospectus supplement.
The prospectus supplement relating to any
warrants we offer will include specific terms relating to the offering. These terms will include some or all of the following:
|
·
|
the title of the warrants;
|
|
·
|
the aggregate number of warrants offered;
|
|
·
|
the designation, number and terms of the debt securities, common shares or other securities purchasable upon exercise of the
warrants and procedures by which those numbers may be adjusted;
|
|
·
|
the exercise price of the warrants;
|
|
·
|
the dates or periods during which the warrants are exercisable;
|
|
·
|
the designation and terms of any securities with which the warrants are issued;
|
|
·
|
if the warrants are issued as a unit with another security, the date on and after which the warrants and the other security
will be separately transferable;
|
|
·
|
if the exercise price is not payable in U.S. dollars, the foreign currency, currency unit or composite currency in which the
exercise price is denominated;
|
|
·
|
any minimum or maximum amount of warrants that may be exercised at any one time;
|
|
·
|
any terms relating to the modification of the warrants;
|
|
·
|
any terms, procedures and limitations relating to the transferability, exchange or exercise of the warrants; and
|
|
·
|
any other specific terms of the warrants.
|
The terms of any warrants to be issued
and a description of the material provisions of the applicable warrant agreement will be set forth in the applicable prospectus
supplement.
Description
of Purchase Contracts
We may issue purchase contracts for the
purchase or sale of debt or equity securities issued by us or securities of third parties, a basket of such securities, an index
or indices or such securities or any combination of the above as specified in the applicable prospectus supplement.
Each purchase contract will entitle the
holder thereof to purchase or sell, and obligate us to sell or purchase, on specified dates, such securities at a specified purchase
price, which may be based on a formula, all as set forth in the applicable prospectus supplement. We may, however, satisfy our
obligations, if any, with respect to any purchase contract by delivering the cash value of such purchase contract or the cash value
of the property otherwise deliverable as set forth in the applicable prospectus supplement. The applicable prospectus supplement
will also specify the methods by which the holders may purchase or sell such securities and any acceleration, cancellation or termination
provisions or other provisions relating to the settlement of a purchase contract.
The purchase contracts may require us to
make periodic payments to the holders thereof or vice versa, which payments may be deferred to the extent set forth in the applicable
prospectus supplement, and those payments may be unsecured or prefunded on some basis. The purchase contracts may require the holders
thereof to secure their obligations in a specified manner to be described in the applicable prospectus supplement. Alternatively,
purchase contracts may require holders to satisfy their obligations thereunder when the purchase contracts are issued. Our obligation
to settle such pre-paid purchase contracts on the relevant settlement date may constitute indebtedness. Accordingly, pre-paid purchase
contracts will be issued under either the senior indenture or the subordinated indenture.
Description
of Units
As specified in the applicable prospectus
supplement, we may issue units consisting of one or more common shares, debt securities, warrants, purchase contracts or any combination
of such securities. The applicable prospectus supplement will describe:
|
·
|
the terms of the units and of the common shares, debt securities, warrants and/ or purchase contracts comprising the units,
including whether and under what circumstances the securities comprising the units may be traded separately;
|
|
·
|
a description of the terms of any unit agreement governing the units; and
|
|
·
|
a description of the provisions for the payment, settlement, transfer or exchange of the units.
|
Forms of
Securities
Each debt security, warrant and unit will
be represented either by a certificate issued in definitive form to a particular investor or by one or more global securities representing
the entire issuance of securities. Certificated securities in definitive form and global securities will be issued in registered
form. Definitive securities name you or your nominee as the owner of the security, and in order to transfer or exchange these securities
or to receive payments other than interest or other interim payments, you or your nominee must physically deliver the securities
to the trustee, registrar, paying agent or other agent, as applicable. Global securities name a depositary or its nominee as the
owner of the debt securities, warrants or units represented by these global securities. The depositary maintains a computerized
system that will reflect each investor’s beneficial ownership of the securities through an account maintained by the investor
with its broker/dealer, bank, trust company or other representative, as we explain more fully below.
Registered Global Securities
We may issue the registered debt securities,
warrants and units in the form of one or more fully registered global securities that will be deposited with a depositary or its
nominee identified in the applicable prospectus supplement and registered in the name of that depositary or nominee. In those cases,
one or more registered global securities will be issued in a denomination or aggregate denominations equal to the portion of the
aggregate principal or face amount of the securities to be represented by registered global securities. Unless and until it is
exchanged in whole for securities in definitive registered form, a registered global security may not be transferred except as
a whole by and among the depositary for the registered global security, the nominees of the depositary or any successors of the
depositary or those nominees.
If not described below, any specific terms
of the depositary arrangement with respect to any securities to be represented by a registered global security will be described
in the prospectus supplement relating to those securities. We anticipate that the following provisions will apply to all depositary
arrangements.
Ownership of beneficial interests in a
registered global security will be limited to persons, called participants, that have accounts with the depositary or persons that
may hold interests through participants. Upon the issuance of a registered global security, the depositary will credit, on its
book-entry registration and transfer system, the participants’ accounts with the respective principal or face amounts of
the securities beneficially owned by the participants. Any dealers, underwriters or agents participating in the distribution of
the securities will designate the accounts to be credited. Ownership of beneficial interests in a registered global security will
be shown on, and the transfer of ownership interests will be effected only through, records maintained by the depositary, with
respect to interests of participants, and on the records of participants, with respect to interests of persons holding through
participants. The laws of some states may require that some purchasers of securities take physical delivery of these securities
in definitive form. These laws may impair your ability to own, transfer or pledge beneficial interests in registered global securities.
So long as the depositary, or its nominee,
is the registered owner of a registered global security, that depositary or its nominee, as the case may be, will be considered
the sole owner or holder of the securities represented by the registered global security for all purposes under the applicable
indenture, warrant agreement or unit agreement. Except as described below, owners of beneficial interests in a registered global
security will not be entitled to have the securities represented by the registered global security registered in their names, will
not receive or be entitled to receive physical delivery of the securities in definitive form and will not be considered the owners
or holders of the securities under the applicable indenture, warrant agreement or unit agreement. Accordingly, each person owning
a beneficial interest in a registered global security must rely on the procedures of the depositary for that registered global
security and, if that person is not a participant, on the procedures of the participant through which the person
owns its interest, to exercise any rights
of a holder under the applicable indenture, warrant agreement or unit agreement. We understand that under existing industry practices,
if we request any action of holders or if an owner of a beneficial interest in a registered global security desires to give or
take any action that a holder is entitled to give or take under the applicable indenture, warrant agreement or unit agreement,
the depositary for the registered global security would authorize the participants holding the relevant beneficial interests to
give or take that action, and the participants would authorize beneficial owners owning through them to give or take that action
or would otherwise act upon the instructions of beneficial owners holding through them.
Principal, premium, if any, and interest
payments on debt securities, and any payments to holders with respect to warrants or units, represented by a registered global
security registered in the name of a depositary or its nominee will be made to the depositary or its nominee, as the case may be,
as the registered owner of the registered global security. None of Auris Medical Holding AG, its affiliates, the trustees, the
warrant agents, the unit agents or any other agent of Auris Medical Holding AG, agent of the trustees or agent of the warrant agents
or unit agents will have any responsibility or liability for any aspect of the records relating to payments made on account of
beneficial ownership interests in the registered global security or for maintaining, supervising or reviewing any records relating
to those beneficial ownership interests.
We expect that the depositary for any of
the securities represented by a registered global security, upon receipt of any payment of principal, premium, interest or other
distribution of underlying securities or other property to holders on that registered global security, will immediately credit
participants’ accounts in amounts proportionate to their respective beneficial interests in that registered global security
as shown on the records of the depositary. We also expect that payments by participants to owners of beneficial interests in a
registered global security held through participants will be governed by standing customer instructions and customary practices,
as is now the case with the securities held for the accounts of customers in bearer form or registered in “street name,”
and will be the responsibility of those participants.
If the depositary for any of these securities
represented by a registered global security is at any time unwilling or unable to continue as depositary or ceases to be a clearing
agency registered under the Exchange Act, and a successor depositary registered as a clearing agency under the Exchange Act is
not appointed by us within 90 days, we will issue securities in definitive form in exchange for the registered global security
that had been held by the depositary. Any securities issued in definitive form in exchange for a registered global security will
be registered in the name or names that the depositary gives to the relevant trustee, warrant agent, unit agent or other relevant
agent of ours or theirs. It is expected that the depositary’s instructions will be based upon directions received by the
depositary from participants with respect to ownership of beneficial interests in the registered global security that had been
held by the depositary.
Plan of
Distribution
We may sell the securities in one or more
of the following ways (or in any combination) from time to time:
|
·
|
through underwriters or dealers;
|
|
·
|
directly to a limited number of purchasers or to a single purchaser;
|
|
·
|
through any other method permitted by applicable law and described in the applicable prospectus supplement.
|
The prospectus supplement will state the
terms of the offering of the securities, including:
|
·
|
the name or names of any underwriters, dealers or agents;
|
|
·
|
the purchase price of such securities and the proceeds to be received by us, if any;
|
|
·
|
any underwriting discounts or agency fees and other items constituting underwriters’ or agents’ compensation;
|
|
·
|
any initial public offering price;
|
|
·
|
any discounts or concessions allowed or reallowed or paid to dealers; and
|
|
·
|
any securities exchanges on which the securities may be listed.
|
Any initial public offering price and any
discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time.
If underwriters are used in the sale, the
securities will be acquired by the underwriters for their own account and may be resold from time to time in one or more transactions,
including:
|
·
|
negotiated transactions;
|
|
·
|
at a fixed public offering price or prices, which may be changed;
|
|
·
|
at market prices prevailing at the time of sale;
|
|
·
|
at prices related to prevailing market prices; or
|
Unless otherwise stated in a prospectus
supplement, the obligations of the underwriters to purchase any securities will be conditioned on customary closing conditions
and the underwriters will be obligated to purchase all of such series of securities, if any are purchased.
The securities may be sold through agents
from time to time. The prospectus supplement will name any agent involved in the offer or sale of the securities and any commissions
paid to them. Generally, any agent will be acting on a best efforts basis for the period of its appointment.
We may authorize underwriters, dealers
or agents to solicit offers by certain purchasers to purchase the securities at the public offering price set forth in the prospectus
supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. The contracts
will be subject only to those conditions set forth in the prospectus supplement, and the prospectus supplement will set forth any
commissions paid for solicitation of these contracts.
Underwriters and agents may be entitled
under agreements entered into with us to indemnification by us against certain civil liabilities, including liabilities under the
Securities Act, or to contribution with respect to payments which the underwriters or agents may be required to make.
The prospectus supplement may also set
forth whether or not underwriters may over-allot or effect transactions that stabilize, maintain or otherwise affect the market
price of the securities at levels above those that might otherwise prevail in the open market, including, for example, by entering
stabilizing bids, effecting syndicate covering transactions or imposing penalty bids.
Underwriters and agents may be customers
of, engage in transactions with, or perform services for us and our affiliates in the ordinary course of business.
Each series of securities will be a new
issue of securities and will have no established trading market, other than our common shares, which are listed on Nasdaq Global
Market. Any underwriters to whom securities are sold for public offering and sale may make a market in the securities, but such
underwriters will not be obligated to do so and may discontinue any market making at any time without notice. The securities, other
than our common shares, may or may not be listed on a national securities exchange.
Incorporation
of Certain Information By Reference
The SEC allows us to incorporate by reference
information into this document. This means that we can disclose important information to you by referring you to another document
filed separately with the SEC. The information
incorporated by reference is considered to
be a part of this document, except for any information superseded by information that is included directly in this prospectus or
incorporated by reference subsequent to the date of this prospectus.
We incorporate by reference the following
documents or information that we have filed with the SEC
|
·
|
our 2014 Annual Report on Form 20-F for the fiscal year ended December 31, 2014; and
|
|
·
|
the information in Exhibits 99.1 and 99.2 to our report on Form 6-K filed on August 19, 2015.
|
All annual reports we file with the SEC
pursuant to the Exchange Act on Form 20-F after the date of this prospectus and prior to termination or expiration of this registration
statement shall be deemed incorporated by reference into this prospectus and to be part hereof from the date of filing of such
documents. We may incorporate by reference any Form 6-K subsequently submitted to the SEC by identifying in such Form 6-K that
it is being incorporated by reference into this prospectus.
Documents incorporated by reference in
this prospectus are available from us without charge upon written or oral request, excluding any exhibits to those documents that
are not specifically incorporated by reference into those documents. You can obtain documents incorporated by reference in this
document by requesting them from us in writing or at Auris Medical Holding AG, Bahnhofstrasse 21, 6300 Zug, Switzerland or via
telephone at +41 (0)41 729 71 94.
Enforcement
of Civil Liabilities
We are organized under the laws of Switzerland
and our jurisdiction of incorporation is Zug, Switzerland. Moreover, a number of our directors and executive officers and a number
of directors of each of our subsidiaries are not residents of the United States, and all or a substantial portion of the assets
of such persons are located outside the United States. As a result, it may not be possible for investors to effect service of process
within the United States upon us or upon such persons or to enforce against them judgments obtained in U.S. courts, including judgments
in actions predicated upon the civil liability provisions of the federal securities laws of the United States. We have been advised
by our Swiss counsel that there is doubt as to the enforceability in Switzerland of original actions, or in actions for enforcement
of judgments of U.S. courts, of civil liabilities to the extent predicated upon the federal and state securities laws of the United
States. Original actions against persons in Switzerland based solely upon the U.S. federal or state securities laws are governed,
among other things, by the principles set forth in the Swiss Federal Act on International Private Law. This statute provides that
the application of provisions of non-Swiss law by the courts in Switzerland shall be precluded if the result was incompatible with
Swiss public policy. Also, mandatory provisions of Swiss law may be applicable regardless of any other law that would otherwise
apply.
Switzerland and the United States do not
have a treaty providing for reciprocal recognition of and enforcement of judgments in civil and commercial matters. The recognition
and enforcement of a judgment of the courts of the United States in Switzerland is governed by the principles set forth in the
Swiss Federal Act on Private International Law. This statute provides in principle that a judgment rendered by a non-Swiss court
may be enforced in Switzerland only if:
|
·
|
the non-Swiss court had jurisdiction pursuant to the Swiss Federal Act on Private International Law;
|
|
·
|
the judgment of such non-Swiss court has become final and non-appealable;
|
|
·
|
the judgment does not contravene Swiss public policy;
|
|
·
|
the court procedures and the service of documents leading to the judgment were in accordance with the due process of law; and
|
|
·
|
no proceeding involving the same position and the same subject matter was first brought in Switzerland, or adjudicated in Switzerland,
or was earlier adjudicated in a third state and this decision is recognizable in Switzerland.
|
Expenses
The following table sets forth the expenses
(other than underwriting discounts and commissions or agency fees and other items constituting underwriters’ or agents’
compensation, if any) expected to be incurred by us in connection with a possible offering of securities registered under this
registration statement.
|
|
Amount
To Be Paid
|
SEC registration fee
|
|
$
|
11,620
|
|
FINRA filing fee
|
|
|
15,500
|
|
Transfer agent’s fees
|
|
|
*
|
|
Printing and engraving expenses
|
|
|
*
|
|
Legal fees and expenses
|
|
|
*
|
|
Accounting fees and expenses
|
|
|
*
|
|
Miscellaneous
|
|
|
*
|
|
Total
|
|
$
|
|
|
|
*
|
To be provided by a prospectus supplement or a Report on Form 6–K that is incorporated by reference into this prospectus.
|
Legal Matters
The validity of our common shares and certain
other matters of Swiss law will be passed upon for us by Froriep, Zurich, Switzerland. Certain matters of U.S. federal and New
York State law will be passed upon for us by Davis Polk & Wardwell LLP, New York, New York.
Experts
The consolidated financial statements
of Auris Medical Holding AG as of and for the year ended December 31, 2014, incorporated in this Prospectus by reference from
Auris Medical Holding AG’s Annual Report on Form 20-F for the year ended December 31, 2014, have been audited by
Deloitte AG, an independent registered public accounting firm, as stated in their report, which is incorporated herein by
reference. Such consolidated financial statements have been so incorporated in reliance on the report of such firm, given
upon their authority as experts in accounting and auditing.
The current address of Deloitte AG is General
Guisan-Quai 38, 8002 Zurich, Switzerland, phone number +(41) 58 279 60 00.
The consolidated financial statements of
Auris Medical Holding AG (formerly Auris Medical AG) as of December 31, 2013 and for each of the years in the two-year period ended
December 31, 2013, have been incorporated by reference herein in reliance upon the report of KPMG AG, independent registered public
accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing.
The current address of KPMG AG is Badenerstrasse
172, CH-8004 Zurich, Switzerland.
Auris Medical Holding
AG
Up to $35,000,000
Common Shares
_______________
PROSPECTUS SUPPLEMENT
_______________
June 1, 2016
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Jul 2023 to Jul 2024